UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

(Mark One)

x	Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
☒	Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
	For the fiscal year ended December 31, 2018.
	For the fiscal year ended December 31, 2019.
OR
¨	Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934
☐	Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934
	for the transition period from __________ to__________

Commission File Number: 333-210091

Lazuriton Nano Biotechnology (U.S.A.) Inc.

(Exact name of registrant as specified in its charter)

Nevada		37-1786808
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

341, Sec. 2, Wanshou Road, 10^th Floor

Guishan District, Taoyuan City, 333, Taiwan (Republic of China)

(Address of principal executive offices, Zip Code)

011-886-3-329-5585

(Registrant’s telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act: None

Securities Registered Pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o ☐ No x ☒

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x ☐ No ¨ ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ¨ ☒ No x ☐

Indicate by check mark whether registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) x ☒

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨☐ Accelerated filer ¨☐ Non-accelerated filer ¨☐ Smaller reporting company x☒ Emerging Growth Company x☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x ☒ No ¨ ☐

At June 2928, ~~2018~~2019, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $75892,~~438,531~~159.

The number of shares of registrant’s common stock outstanding, as of ~~June~~December 331, 2019, was 100,000,000.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered n/a n/a n/a

TABLE OF CONTENTS

PART I
	Item 1.	Business	3	3
	Item1A.	Risk Factors	7	7
	Item1B.	Unresolved Staff Comments		7
	Item 1B.	Unresolved Staff Comments	7
	Item 2.	Properties	7	7
	Item 3.	Legal Proceedings	7	7
	Item 4.	Mine Safety Disclosures	7	7
PART II
	Item 5.	Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	8	8
	Item 6.	Selected Financial Data	9	9
	Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10	10
	Item7A.	Quantitative and Qualitative Disclosures about Market Risk	13	14
	Item 8.	Financial Statements and Supplementary Data	14	15
	Item 9.	Changes In and Disagreements with Accountants on Accounting and Financial Disclosure	15	16
	Item 9A.	Controls and Procedures	15	16
	Item 9B.	Other Information	16	17
PART III
	Item 10.	Directors, Executive Officers and Corporate Governance	17	18
	Item 11.	Executive Compensation	21	22
	Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	24	25
	Item 13.	Certain Relationships and Related Transactions and Director Independence	25	26
PART IV
	Item 14.	Principal Accountant Fees and Services	26	27
	Item 15.	Exhibits, Financial Statement Schedules	27	28
	Item 16.	Form 10-K Summary	27	28
SIGNATURES			28	29

Table of Contents

PART I

Except where the context otherwise requires and for purposes of this annual report only:

the terms “we,” “us,” “our,” “issuer,” “the Company,” “our Company” refers to Lazuriton Nano Biotechnology (U.S.A.) Inc., a Nevada corporation;

the term “the Manufacturer” refers to Lazuriton Nano Biotechnology Co., Ltd., a Taiwanese corporation;

all references to “U.S. dollars”, “dollars”, and “$” are to the legal currency of the United States.

For the purposes of clarification, this annual report follows English naming convention of first name followed by last name, regardless of whether an individual’s name is Chinese or English. For example, the name of our president and member of our board of directors is “Chih-Yuan Hsiao,” even though, in Chinese, his name would be presented as “Hsiao Chih-Yuan”.

Item 1. Business.

Description of Business

General Information

We were incorporated in the State of Nevada on June 2, 2015. Since inception, we have not generated any revenues and have an accumulated deficit of $~~456~~528,~~761~~536, as of December 31, ~~2018~~2019.

We have never been a party to any bankruptcy, receivership or similar proceeding, nor have we undergone any material reclassification, merger, consolidation, purchase or sale of a significant amount of assets not in the ordinary course of business.

We have yet to commence any significant operations. As of the date of this annual report, we have had only limited start-up operations and have not generated revenues. We will not be profitable until we derive sufficient revenues and cash flows from sales of fertilizer products made by the Manufacturer (the “Nano fertilizer products”). Our administrative office is located at 341, Sec. 2,Wanshou Rd., 10^th Floor, Guishan District, Taoyuan City, 333, Taiwan (Republic of China).

Our fiscal year ~~ends~~end on is December 31.

As of the date of this annual report, we have not sold any Nano products (including fertilizer and food products), nor have we generated any revenue from our operations.

Business Overview

We anticipate that we will receive revenues from the sale of the Nano fertilizer products, which are manufactured in Taiwan. We plan to market and sell the Nano fertilizer products to resellers of fertilizers who are aware of the needs of the targeted customers. Additionally, we may target individual farmers and households.

Since the date of inception (June 2, 2015), our activities have been primarily developmental, e.g., formation of the Company, development of our business plan, negotiation of the marketing and distribution agreement (the “Marketing Agreement”) with the Manufacturer (as defined below) and research regarding marketing and distribution methods and strategies; we have yet to commence planned operations to any significant measure.

Table of Contents

Our current management is comprised of Chih-Yuan Hsiao, our president, principal executive officer, and a member of our board of directors; Ching-Chia Chuang, our secretary, principal financial officer, ~~and~~ treasurer; ~~Yu-Chih~~and ~~Hsiao,~~ a member of ~~our~~the board; ~~of directors, Min~~Yu-~~Tsung~~Chih Hsiao, a member of our board of directors;, and ~~Siu~~Min-Tsung ~~Wan Claire Hong~~Hsiao, a member of our board of directors. Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao are brothers. Ching-Chia Chuang is a cousin of Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao.

Our officers and directors held approximately 60.62% of the Company’s issued and outstanding shares of common stock as of ~~June~~December 331, 2019. Additionally, our president and a member of our board of directors, Chih-Yuan Hsiao, and our other directors, Yu-Chih Hsiao and Min-Tsung Hsiao, hold a majority of the issued and outstanding shares of common stock of the Manufacturer. As the Manufacturer is the sole supplier of the Nano fertilizer products that we intend to market and distribute, to the extent that Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao participate in the management of the Manufacturer with respect to the Manufacturer’s relationship with the Company, there is a conflict of interest between the Manufacturer and us. Our officers and directors are aware of their fiduciary duties to the Company and its shareholders and will make every effort to consider the best interests of the Company and its shareholders in connection with the transactions and relationships between the Company and the Manufacturer. As of the date of this annual report, the Company did not have Director & Officer liability insurance.

We anticipate that we will receive revenue from the distribution and sale of the Nano fertilizer products. We plan to market and sell the Nano fertilizer products to resellers of fertilizers who are aware of the needs of their customers. Additionally, we may target individual farmers and households.

During ~~2018~~2019, our operations were limited to seeking business opportunities in connection with the marketing and distribution of the Nano fertilizer products. We are in the process of establishing retail relationships with various distributors and retailers in Asia.

We believe that we may establish sufficient business relationships which will enable us to sell and distribute the Nano fertilizer products.

Presently, we have no employees. Our officers and directors are responsible for all planning, development and operational duties and will continue to do so throughout the early stages of our development. Human resource planning will be a part of an ongoing process that will include regular evaluation of our operations.

We intend to hire employees at such time as we determine ~~it is~~ appropriate. We cannot provide any assurance or guarantee on the date on which we will hire employees.

Marketing and Distribution Agreement

Effective December 1, 2015, we entered into the Marketing Agreement with the Manufacturer, whereby the Manufacturer authorizes the Company to market, sell and distribute those Nano fertilizer products manufactured by the Manufacturer. The Marketing Agreement grants the Company a non-exclusive right to market, sell and distribute the Nano fertilizer products in Asia, with the exception of Taiwan. The Marketing Agreement is effective as of December 1, 2015, and continues for one year thereafter and is renewed automatically for periods of one year each, unless one party gives notice to the other party at least 30 days prior to the expiration of the said agreement of its intention not to renew. As of the date of ~~this~~June ~~annual~~30, ~~report~~2021, no party to this Marketing Agreement gave notice to terminate this agreement and the terms of this Marketing Agreement were effective. The Company is making efforts to distribute Nano fertilizer and food products in Taiwan, mainland China and Japan.

Nano Fertilizer Products

Nano fertilizers may improve the efficiency of delivering various nutrients to plants and crops because the nano-level particles make it easy and more efficient for the plants to absorb the fertilizers. The plants, vegetables and crops sprayed with Nano fertilizer products have shown to grow faster, enjoy 20-30% longer life span, be less likely to have pests, and have an enhanced food production rates with higher quality. Use of Nano fertilizers helps avoid certain common side effects of non-Nano fertilizers, such as inconsistent plant sizes, shapes and colors caused by uneven distribution of fertilizers. At the same time, the Manufacturer observed that Nano fertilizer products have the potential of reducing soil toxicity caused by the use of traditional non-Nano fertilizers.

Table of Contents

The Nano fertilizers that we will market, sell and distribute are listed below:

	#1-Nano Organic Compound Fertilizer:
	o	Ingredients include nitrogen, phosphorus anhydride, potassium oxide and citric acid-soluble magnesium oxide.
	o	May be used on vegetables and fruit trees during vegetative growth and reproductive growth.
	#3-Nano Low Nitrogen High Phosphorus High Potassium Compound Fertilizer
	o	Ingredients include nitrogen, phosphorus and potassium oxide.
	o	May be used on vegetables, fruit trees and floral crops to promote flowering.
	#5-Nano High Phosphorus High Potassium Compound Fertilizer
	o	Ingredients include nitrogen, phosphorus and potassium oxide.
	o	May be used on vegetables and fruit trees to improve the quality of the crop and the sweetness of the fruit.

The Nano Fertilizer Products may be applied in other manners depending on the targeted crops and vegetables.

The Manufacturer

The Manufacturer, Lazuriton Nano Biotechnology Ltd., a Taiwanese corporation, manufactures the Nano fertilizer products in Taiwan.

Chih-Yuan Hsiao is the president and sole director of the Manufacturer. Mr. Hsiao, currently, also owns 88.4% of the issued and outstanding shares of common stock of the Manufacturer. Yu-Chih Hsiao is the factory manager of the Manufacturer and owns 5.80% of the issued and outstanding shares of its common stock. Min-Tsung Hsiao also owns 5.80% of the issued and outstanding shares of the Manufacturer’s common stock.

As the Manufacturer is the sole supplier of the Nano fertilizer products that we intend to market and distribute, to the extent that Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao participate in the management of the Manufacturer with respect to the Manufacturer’s relationship with the Company, there is a conflict of interest regarding the affairs of the Manufacturer and the affairs of the Company. We have not yet formulated a policy for handling conflicts of interest; however, Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao are aware of their fiduciary duties to the Company and its shareholders and will make reasonable efforts to serve the best interests of the Company and its shareholders.

Revenues

We anticipate that we ~~will~~may receive revenue from the sale of the Nano fertilizer products. The Nano fertilizer products will be primarily sold through resellers of fertilizers who are aware of the needs of the targeted customers. Additionally, we may target individual farmers and households. The cost of each Nano fertilizer product may vary, depending on a number of factors, including the (i) amount of the Nano fertilizer product that is being purchased; (ii) cost of raw materials; (iii) volume of products that were generated within the same time period; (iv) the use of the fertilizers; and (v) depreciation of the machines and equipment.

As of the date of this annual report, we have not sold any of the Nano fertilizer products nor have we generated any revenue from operations. Our operations to date have been devoted primarily to development activities, e.g., development of our business plan, negotiation of the Marketing Agreements with the Manufacturer and research regarding the marketing and distribution methods and strategies.

Table of Contents

Marketing

We plan to market and sell the Nano fertilizer products to resellers of fertilizers who are aware of the needs of the targeted customers. Additionally, we may target individual farmers and households.

We will regularly evaluate the market response for our existing products and perform appropriate trend analysis. We anticipate that such evaluation will be to review all sales to analyze which Nano fertilizer products are selling. Additionally, we anticipate that we may engage one or more local marketing or advertising companies which can assist us to understand the various trends.

Upon receipt of additional funding, we will increase the budget allotted for marketing and advertising and use the funds to expand our target markets. We believe we can gain a greater market share of Nano fertilizer consumers by expanding our target market to supermarkets and agricultural chain stores. At this time, we are unsure if, and when, we will receive that additional funding.

Need for any Government Approval – Environment Laws

We are subject to evolving laws and regulations administered by governmental authorities at national, provincial and city levels. Our operations may require us to comply with regulations relating to a comprehensive array of subjects, such as environmental protection and fire hazard control. We believe we are currently in compliance with these laws and regulations in all material respects. We may be required to incur significant costs to comply with these laws and regulations in the future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could have a material adverse effect on our financial condition and results of operations.

Patents, Trademarks and Licenses

Presently, the Company does not own any patents or trademarks. The following table lists the trademarks that the Manufacturer, an affiliate of the Company has registered. The fertilizer products we intend to distribute and sell will bear those marks.

Owner of the Mark	Mark	Jurisdiction	Period
Lazuriton Nano Biotechnology Co., Ltd.		Taiwan	August 1, 2012 to July 31, 2022
Lazuriton Nano Biotechnology Co., Ltd.		Taiwan	December 1, 2012 to November 30, 2022
Lazuriton Nano Biotechnology Co., Ltd.		People’s Republic of China	May 21, 2014 to May 20, 2024

Table of Contents

Seasonality

In most regions where we plan to sell the Nano fertilizers, various types of vegetables, fruit trees and floral crops grow at different times and may benefit from the Nano fertilizer products. Accordingly, we do not anticipate a greater or lesser demand from our target customers for the Nano fertilizer products during different seasons. Because the Nano fertilizer products can be manufactured and used all year round, we believe our operations and sales will not be subject to seasonality.

Competition

The fertilizer business is characterized by vigorous competition throughout the world. Brand recognition, price, service, quality and availability are some of the factors that impact consumers’ choices among competing products and brands. Advertising, promotion, merchandising and the pace of new product introductions have significant impacts on consumers’ buying decisions. We will face completion from a large number of fertilizer companies, some of which may have substantially greater resources than we do.

Our principal competitors are Hsin Fang Nano Technology Ltd. and Unicat Nano Advanced Materials & Devices Technology Ltd. We will also face competition from a number of independent brands, as well as some retailers that have developed their own brands.

Our products have relatively low manufacturing costs, which may allow us to offer competitive pricing to our customers. Additionally, we believe that by providing outstanding customer service we can build customer loyalty to our brand.

Employees and Employment Agreements

Presently, we have no employees. Our president, Chih-Yuan Hsiao, is responsible for the primary operations and development of the Company and its subsidiaries. There is no employment or similar agreement between the Company and Mr. Hsiao.

Item 1A. Risk Factors.

Not applicable for smaller reporting companies.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

We do not own any real estate property. Mr. Chih-Yuan Hsiao, our president and chairman of the Board, entered into a lease that allowed the Company to operate at the address of 341 Wanchou Rd., 10th Floor, Guishan District, Taoyuan City, 333, Taiwan (Republic of China). The monthly rent is 40,000 NTD (approximately $1,267 U.S. dollars), excluding the electricity, gas and water expenses. The lease for such office space will end on May 31, 2020. WeUpon ~~consider~~expiration of our ~~current~~lease, ~~office~~we ~~arrangement~~extended ~~adequate~~the ~~and~~lease ~~will~~on ~~reassess~~a ~~our~~monthly ~~needs~~basis ~~based~~and ~~upon~~planned to move the ~~future~~office ~~growth~~to ofa ~~the~~new ~~Company~~location.

Item 3. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings, which may arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these, or other matters, may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

Item 4. Mine Safety Disclosures.

Not applicable.

Table of Contents

PART II

Item 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

No public market currently exists for shares of our common stock.

There were ~~147~~ 148 holders of record of our common stock as of ~~June~~December 331, 2019.

We paid no dividends on our common stock induring ~~2018~~the fiscal year of 2019. We do not have a policy of paying regular dividends and do not expect to pay any dividends on our common stock in the foreseeable future. We currently intend to retain any future earnings for our business. The payment of any future dividends on our common stock will be determined by our Board of Directors subject to our business and financial conditions, applicable Nevada laws and federal laws and other factors.

Recent Transactions Involving Unregistered Securities

None.

Common Stock

As of ~~June~~December 331, 2019, the outstanding number of shares of our common stock was 100,000,000. All our outstanding common shares are validly issued, fully paid and non-assessable.

Each share of our common stock entitles the shareholder one vote on any and all matters such shareholder is entitled to vote at a shareholders’ annual or special meeting. There are no cumulative voting rights, which mean that the shareholder or shareholders owning 50% of the issued and outstanding shares in our capital stock can elect the entire board of directors. Therefore, any shareholder or shareholders, cumulatively with less than 50% of the voting power, cannot elect any director to the board of directors on their won. Pursuant to the provisions of Section 78.320 of the Nevada Revised Statues (the “NRS”), at least a majority of the outstanding shares of capital stock entitled to vote must be present, in person or by proxy, at any meeting in favor of the action exceeds the number of votes cast in opposition to the action, provided, however, that directors may be elected by a plurality of the votes of the shares present at the meeting and entitled to vote. Certain fundamental corporate changes, such as the liquidation and business combination, require the approval of holders of a majority of the outstanding shares entitled to vote.

Holders of our common stock have no pre-emptive rights, no conversion rights and no subscription rights. There are no redemption or sinking fund provisions applicable to our common stock.

Preferred Stock

AtAs ~~present~~of the date of this annual report, we have no preferred stock authorized.

Dividends

The holders of our common stock are entitled to receive dividends on a pro rata based on the number of shares held, when and if declared by our Board of Directors, from funds legally available for that purpose. NRS Section 78.288 prohibits us from declaring dividends where, after giving effect to the distribution of the dividend we would not be able to pay our debts as they become due in the normal course of business; or except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution. We do not, however, intend to pay any dividends in the foreseeable future and currently intend to retain all future earnings to finance our business.

Table of Contents

Our shareholders are not entitled to preference as to dividends or interest; pre-emptive rights to purchase new issues of shares; preference upon liquidation; or any other special rights or preferences.

There are no restrictions on dividends under any loan or other financing arrangements.

We paid no dividends on our common stock in the fiscal year of ~~2018~~2019. We do not have a policy of paying regular dividends and do not expect to pay any dividends on our common stock in the foreseeable future. We currently intend to retain any future earnings for our business. The payment of any future dividends on our common stock will be determined by our Board of Directors and will depend on business conditions, our financial earnings and other factors.

Outstanding Stock Options, Purchase Warrants and Convertible Securities

We have no outstanding stock options, purchase warrants or convertible securities.

Equity Compensation Plans, Bonus Plans

We have not established any equity incentive plans. We have no outstanding Compensation Committee.

Pension Benefits

We do not have any defined benefit pension plans.

Nonqualified Deferred Compensation

We do not maintain any nonqualified deferred compensation plans.

Debt Securities

As of ~~April~~December 331, 2019, we owed Mr. Hsiao approximately $~~215~~233,~~000~~288 pursuant to that Funding Commitment (as defined below) which was disclosed in the Company’s annual report on Form 10-K filed on April 3, 2018. The Funding Commitment was valid and outstanding as of the date of this annual report on Form 10-K.

Except as disclosed above, we have no debt securities outstanding.

Repurchase Programs

There is currently no share repurchase program pending..

Item 6. Selected Financial Data.

As a smaller reporting company, we are not required to provide the information required by this item.

Table of Contents

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

Some of the statements contained in this Form 10-K that are not historical facts are “forward-looking statements” which can be identified by the use of terminology such as “estimates,” “projects,” “plans,” “believes,” “expects,” “anticipates,” “intends,” or the negative or other variations, or by discussions of strategy that involve risks and uncertainties. We urge you to be cautious of the forward-looking statements, that such statements, which are contained in this Form 10-K, reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting our operations, market growth, services, products, and licenses. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of the risks we face, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, our performance or achievements, or industry results, to differ materially from those contemplated by such forward-looking statements include without limitation:

1.	Our ability to attract and retain management and key employees;

2.	Our ability to generate customer demand for our products;

3.	The intensity of competition; and

4.	General economic conditions.

All written and oral forward-looking statements made in connection with this annual report that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred an accumulated deficit of $~~456~~528,~~761~~536 as of December 31, ~~2018~~2019. As of December 31, ~~2018~~2019, the Company had not generated revenue, as the business operations ~~have~~had ~~been~~ focused on developing our business plan and market research. This raises substantial doubt about the Company’s ability to continue as a going concern. The opinion of our independent registered public accountants on our audited financial statements as of and for the year ended December 31, ~~2018~~2019 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon raising capital from financing transactions and future sales.

Overview

The following information should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this Form 10-K. The following information specifies forward looking statements that anticipate our business plan, estimates and beliefs. Our actual results could differ materially from those contemplated in those forward looking statements.

Description of Business

General Information

We were incorporated in the State of Nevada on June 2, 2015 and our operations are based in Taiwan. Since inception, we did not generate any revenues ~~and~~or ~~accumulated~~net ~~losses~~income ~~in the amount of $456,761~~ as of December 31, ~~2018~~2019.

Table of Contents

We have yet to commence planned operations to any significant measure. As of the date of this annual report, we, have had only limited start-up operations and have not generated revenues. We will not be profitable until we derive sufficient revenues and cash flows from sales of Nano fertilizer products. Our administrative office is located at 341 Sec. 2, Wanshou Rd., 10^th Floor, Guishan District, Taoyuan City, 333, Taiwan.

Our fiscal year ends on December 31.

As of the date of this annual report, we have not sold any Nano fertilizer products, nor have we generated any revenue from operations.

Going Concern

The Company has incurred losses to date. The accompanying financial statements have been prepared assuming the Company will continue as a going concern.

For the period ended December 31, ~~2018~~2019, the Company had limited operations. As of December 31, ~~2018~~2019, the Company has not emerged from the development stage. In view of these matters, the Company’s ability to continue as a going concern is dependent upon its ability to obtain financing and upon future profitable operations from the development of its planned business. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities and/or loans by Chih-Yuan Hsiao, its president and a member of its board of directors. On February 9, 2017, Mr. Hsiao signed a written funding commitment (the “Funding Commitment”) to lend the Company as much as $400,000 to pay the operating expenses of the Company for a period of 12 months. The Funding Commitment automatically renews on each anniversary of the Funding Commitment for one additional year term unless either the Company or Mr. Hsiao elects to terminate the Funding Commitment. Any amount advanced by Mr. Hsiao pursuant to that Funding Commitment shall not accrue interest and is payable on demand. As of the date of this report, there is no notice to demand the repayment of the loans provided by Mr. Hsiao nor any notice to terminate the Funding Commitment. We can provide no guarantee or assurance that in the event of that demand, we can pay the amount demanded, or any other amount, on the date for which such payment is due. Because Mr. Hsiao is our president and a member of our board of directors, we believe the Funding Commitment is a related party transaction. However, our board believes that the terms of the Funding Commitment are not unreasonable. As of ~~April~~December 331, 2019, we owed Mr. Hsiao approximately $~~215~~233,~~000~~288 pursuant to that Funding Commitment. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. As shown in the accompanying financial statements, the Company had incurred an accumulated deficit of $~~456~~528,~~761~~536 as of December 31, ~~2018~~2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

~~Critical Accounting Policies and Estimates~~Classification

~~The~~Certain ~~preparation~~classifications ofhave ~~financial~~been ~~statements~~made into ~~conformity with generally accepted accounting principles in~~ the ~~United~~prior ~~States~~year offinancial ~~America,~~statements ~~requires~~to ~~management~~conform to ~~make estimates and assumptions that affect~~ the ~~reported~~current ~~amounts~~year ofpresentation. ~~assets~~The ~~and~~reclassification ~~liabilities~~had ~~and~~no ~~disclosure~~impact ofon ~~contingent~~previously ~~assets and liabilities at the date of the financial statements and the~~ reported ~~amounts~~net ofloss ~~revenue~~or ~~and~~accumulated ~~expenses during the reporting period~~deficit. ~~Actual results could differ from those estimates.~~

11Cash ~~Table~~and ofCash ~~Contents~~Equivalents

Cash and ~~Cash~~cash ~~Equivalents~~equivalents include cash and all highly liquid instruments with original maturities of three months or less.

~~Cash~~11 ~~and~~Table ~~cash equivalents include cash and all highly liquid instruments with original maturities~~ of ~~three months or less.~~Contents

Net Loss ~~per~~Per Share

Basic income (loss) per share is computed by dividing net income by weighted average number of shares of common stock outstanding during each period. Diluted ~~loss~~income per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. AsAt of December 31, 2019 and 2018, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of both December 31, ~~2018~~2019 and ~~2017~~2018, respectively.

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company ~~recognize~~recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, by using enacted tax rates in effect in the years the differences ~~are expected to reverse~~. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.

Recent Accounting Pronouncements

In December ~~2017~~2019, the ~~Securities~~FASB ~~and Exchange Commission~~ issued ~~Staff Accounting Bulletin (“SAB”) No. 118 (as further clarified by FASB~~ ASU ~~2018~~2019-0512, Income Taxes (Topic 740): ~~“Amendments~~Simplifying tothe ~~SEC Paragraphs Pursuant to SEC Staff~~ Accounting ~~Bulletin No. 118”) to provide guidance~~ for ~~companies~~Income ~~that~~Taxes, ~~may~~as ~~not~~part ~~have~~of ~~completed~~its ~~their~~overall ~~accounting~~simplification ~~for~~initiative ~~the~~to ~~income~~reduce ~~tax~~costs ~~effects of the Tax Cut~~ and ~~Jobs~~complexity ~~Act (“Tax Act”) in the period~~ of ~~enactment,~~applying ~~which is the period that includes December 22, 2017. SAB No. 118 provides for a provisional one-year measurement period for entities to finalize their~~ accounting ~~for~~standards ~~certain~~while ~~income~~maintaining ~~tax~~or ~~effects~~improving ~~related to~~ the ~~Tax~~usefulness ~~Act.~~of ~~SAB No. 118 provides guidance where: (i)~~ the ~~accounting~~information ~~for~~provided ~~the~~to ~~income~~users ~~tax effect~~ of ~~the~~financial ~~Tax~~statements. ~~Act~~The ~~is complete and reported in the Tax Act~~FASB’s ~~enactment~~amendments ~~period,~~primarily ~~(ii)~~impact ~~the~~ASC ~~accounting~~740, ~~for~~Income ~~the~~Taxes, ~~income~~and ~~tax~~may ~~effect~~impact ofboth ~~the~~interim ~~Tax Act is incomplete~~ and ~~reported~~annual asreporting ~~provisional~~periods. ~~amounts~~ASU ~~based~~2019-12 onwill ~~reasonable~~be ~~estimates~~effective ~~(to~~for ~~the~~fiscal ~~extent~~years ~~determinable)~~beginning ~~subject~~after toDecember ~~adjustments~~15, ~~during a limited measurement period until complete~~2020, and ~~(iii)~~interim ~~accounting~~periods ~~for~~within ~~the~~those ~~income~~fiscal ~~tax~~years ~~effect~~and ofearly ~~the~~adoption ~~Tax Act~~ is not reasonably estimable (no related provisional amounts are reported in the enactment period) and entities would continue to apply accounting based on tax law provisions in effect prior to the Tax Act enactment until provisional amounts are reasonably estimablepermitted. ~~SAB No. 118 requires disclosure of the reasons for incomplete accounting additional information or analysis needed, among other relevant information.~~ The Company is ~~continuing~~currently toevaluating ~~gather~~the ~~additional~~impact ~~information~~of toadopting ~~determine~~ASU ~~the final impact~~2019-12.

12Results ~~Table~~ of ~~Contents~~Operations

InYear ~~February~~ended ~~2018,~~December ~~the FASB issued ASU No~~31, ~~2018-02,~~2019 ~~“Income~~compared Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this Update allow a reclassification from accumulated other comprehensive income to ~~retained earnings for stranded tax effects resulting from~~ the ~~Tax~~year ~~Cuts~~ended and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this Update are effective for all entities for fiscal years beginning after December 1531, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The Company is currently evaluating the impact of adopting this new guidance on its financial position, results of operations, statement of comprehensive income, and cash flows.

~~Results~~Net ofrevenue: ~~Operations~~We did not generate any revenue for the years ended December 31, 2019 and 2018. We have had limited business operations since incorporation.

~~The~~General ~~following~~and ~~presents~~administrative ~~the~~expenses: ~~results~~General and administrative expenses primarily consist of legal and professional service fees. General and administrative expenses were $71,775 for the ~~Company~~year ended December 31, 2019, as compared to $92,526 for the year ended December 31, 2018, which represented a decrease of $20,751, or 22%. The decrease in general and ~~2017~~administrative expenses was primarily attributable to the decrease in accounting, legal and professional fees.

~~Net~~Other ~~Revenues~~income: WeOther ~~generated~~income nomainly ~~revenue~~consists ~~and~~of ~~incurred~~interest ~~zero~~income. ~~cost~~Other ofincome ~~sales~~was $0 for the ~~years~~year ended December 31, 2019, as compared to $4 for the year ended December 31, 2018, ~~and~~representing ~~2017~~a decrease of $4, ~~respectively~~or 100%. The decrease was not considered a substantial change.

~~General~~Net ~~and Administrative Expense~~loss: ~~General~~ ~~and~~Our ~~administrative~~net ~~expenses~~loss ~~primarily~~was ~~consist of legal~~$71,775 ~~accounting,~~for ~~and~~the ~~other~~year ~~professional~~ended ~~service~~December ~~fees.~~31, ~~General and administrative expenses have decreased by $83~~2019,~~338,~~ oras ~~(47)~~compared % to $92,~~526~~522 for the year ended December 31, 2018, ~~from~~which ~~$175,864~~represented ~~for~~a ~~the~~decrease ~~year~~of ~~ended December 31~~$20,747, ~~2017~~or 22%. The decrease in ~~those~~net ~~expenses~~loss was ~~primarily~~a ~~attributable~~result toof athe decrease in ~~consulting~~general ~~fees~~and administrative expenses.

~~Loss~~12 ~~from~~Table ~~Operations:~~of Loss from operations for the year ended December 31 2018 was $92,526 compared to $175,864 for the year ended December 31, 2017. The decrease was mainly due to the decrease in general and administrative expense.Contents

~~Other~~Liquidity ~~Income (expense): Other income was $4~~ and $8Capital for the years ended December 31, 2018 and 2017, respectively. This represents decreased interest income of $4, or (50) %. The interest income generated during the years ended December 31, 2018 and 2017 was not substantially different.Resources

~~Net~~Cash ~~Loss:~~and ~~Net~~cash ~~loss~~equivalents ~~was~~were $921,~~522~~347 ~~for~~at ~~the~~December ~~year~~31, ~~ended~~2019 and $1,197 at December 31, 2018. Our total current assets were $1,347 at December 31, 2019, as compared to $~~175~~2,~~856~~119 ~~for~~at ~~the year ended~~ December 31, ~~2017~~2018. ~~The~~Our ~~decrease~~total incurrent ~~net~~liabilities ~~loss~~were ~~was~~$269,883 ~~due~~at December 31, 2019, as compared to ~~the~~$198,880 ~~reasons~~at ~~described~~December ~~above~~31, 2018.

13We ~~Table~~had negative working capital of ~~Contents~~$268,536 at December 31, 2019, compared to negative working capital of $196,761 at December 31, 2018. The increase in negative working capital was primarily due to the increase in due to related parties.

~~Liquidity~~Net cash provided by operating activities was $150 during the year ended December 31, 2019, compared to $4 during the year ended December 31, 2018. The increase in the cash provided by operating activities was primarily due to the decreased net loss and ~~Capital~~increase ~~Resources~~in accrued expenses, partially offset by the decrease in due to related parties.

~~Cash~~We ~~and~~had ~~cash~~no ~~equivalents~~net ~~were~~cash ~~$1,197~~flow atfrom ~~December~~investing ~~31,~~or ~~2018,~~financing ~~and~~activities ~~$1,193~~during atthe ~~December~~years ~~31,~~ended ~~2017. Our total current assets were $2,119 at~~ December 31, ~~2018,~~2019 asand ~~compared to $1,193 at December 31, 2017. Our total current liabilities were $198,880 at December 31,~~ 2018~~, as compared to $105,432 at December 31, 2017~~.

WeNet ~~had~~change ~~negative~~in ~~working~~cash ~~capital~~and ofcash ~~$(196,761)~~equivalents atwas ~~December~~an ~~31,~~increase ~~2018,~~of ~~compared~~$150 toduring ~~negative~~the ~~working~~year ~~capital~~ended ~~of $(104,239) at~~ December 31, ~~2017. The increase in negative working capital in the amount of $92~~2019,~~522~~ orcompared ~~88.8% was primarily due~~ to an increase inof ~~due~~$4 toduring ~~related parties, partially offset by~~ the ~~increase~~year inended ~~cash~~December ~~and~~31, ~~cash equivalents and prepaid expenses~~2018.

~~Net~~Total ~~cash~~capital ~~flow~~expenditures ~~provided~~were ~~by operating activities was~~ $40 during the ~~year~~years ended December 31, ~~2018,~~2019 compared to net cash used in operating activities of $299,735 for the year ended December 31, 2017. The decrease in the cash used in operating activities was primarily attributable to the decrease in net loss and ~~the increase in due to related parties~~2018.

WeDuring ~~had~~the notwelve ~~cash~~(12) ~~flow~~months from ~~investing~~January ~~activities~~1, ~~during~~2021 ~~the~~to ~~years ended~~ December 31, ~~2018~~2021, we anticipate capital expenditures to be approximately $100,000 to $120,000, with the majority of the capital expenditures planned for professional services and ~~2017~~seeking business opportunities in connection with the marketing and distribution of the Nano fertilizer and food products.

Net cash provided by financing activities was $0 during the year ended December 31, 2018, as compared to $200,000 during the year ended December 31, 2017. The decrease in net cash provided by financing activities was primarily because we did not sell any new common stock for cash during the year ended December 31, 2018.Inflation

~~Capital~~Our ~~Expenditures~~opinion is that inflation has not had, and is not expected to have, a material effect on our operations.

~~Total~~Climate ~~capital expenditures were $0 during the years ended December 31, 2018 and 2017.~~Change

~~Inflation~~Our opinion is that neither climate change, nor governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations.

~~Our~~Off-Balance ~~opinion~~Sheet ~~is that inflation has not had, and is not expected to have, a material effect on our operations.~~Arrangements

~~Climate~~We ~~Change~~did not have any off-balance sheet arrangements as of December 31, 2019.

~~Our~~Item ~~opinion~~7A. isQuantitative ~~that~~and ~~neither~~Qualitative ~~climate~~Disclosures ~~change,~~about ~~nor~~Market ~~governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations~~Risk.

~~Off-Balance~~As ~~Sheet~~a ~~Arrangements~~smaller reporting company, we are not required to provide the information required by this item.

We13 ~~did~~Table ~~not have any off-balance sheet arrangements as~~ of ~~December 31, 2018.~~Contents

Item 7A8. ~~Quantitative~~Financial Statements and ~~Qualitative~~Supplementary ~~Disclosures about Market Risk~~Data.

AsLazuriton aNano ~~smaller~~Biotechnology ~~reporting~~(U.S.A.) ~~company, we are not required to provide the information required by this item~~Inc.

14Financial ~~Table~~Statements offor ~~Contents~~the Years Ended

~~Item~~December 8.31, ~~Financial~~2019 ~~Statements~~ and ~~Supplementary Data.~~2018

~~Lazuriton~~14 ~~Nano~~Table ~~Biotechnology~~of ~~(U.S.A.) Inc.~~Contents

~~Financial~~FINANCIAL ~~Statements~~STATEMENT ~~for the Years Ended~~ SCHEDULES

December 31, 2018 and 2017

Report of Independent Registered Public Accounting Firm	F-2

Financial Statements:

Balance Sheets as of December 31, 2019 and 2018	F-3

Statements of Operations for the years ended December 31, 2019 and 2018	F-4

Statements of Cash Flows for the years ended December 31, 2019 and 2018	F-5

Statements of Stockholders' Deficit for the years ended December 31, 2019 and 2018	F-6

Notes to Financial Statements	F-7 - F-10

15F-1 Table of Contents

~~FINANCIAL~~REPORT ~~STATEMENT~~OF ~~SCHEDULES~~INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Report of Independent Registered Public Accounting Firm	F-2
Financial Statements:
Balance Sheets as of December 31, 2018 and 2017	F-3
Statements of Operations for the years ended December 31, 2018 and 2017	F-4
Statements of Cash Flows for the years ended December 31, 2018 and 2017	F-5
Statements of Stockholders' Deficit for the years ended December 31, 2018 and 2017	F-6
Notes to Financial Statements	F-7-F-10

To the Board of Directors and Stockholders of

~~F-1~~Lazuriton ~~Table~~Nano ofBiotechnology ~~Contents~~(U.S.A.) Inc.

~~Audit~~Opinion •on ~~Tax~~the ~~• Consulting •~~ Financial ~~AdvisoryRegistered with Public Company Accounting Oversight Board (PCAOB)~~Statements

~~REPORT~~We OFhave ~~INDEPENDENT~~audited ~~REGISTERED~~the ~~PUBLIC~~accompanying ~~ACCOUNTING~~balance ~~FIRM~~sheets of Lazuriton Nano Biotechnology (U.S.A.) Inc. (the “Company”) as of December 31, 2019 and 2018, the related statements of operations, stockholders’ deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for the years ended December 31, 2019 and 2018, in conformity with the generally accepted accounting principles in the United States of America.

ToGoing ~~the board of directors and shareholders of~~ Concern

~~Lazuriton~~The ~~Nano~~accompanying ~~Biotechnology~~financial (Ustatements have been prepared assuming that the Company will continue as a going concern.S As described in Note 2 to the financial statements, the Company has incurred losses from operations, has a working capital deficit, and is in need of additional capital to grow its operations so that it can become profitable.A These factors raise substantial doubt about the Company’s ability to continue as a going concern.) ~~Inc~~Management’s plans with regard to these matters are described in Note 2. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~Opinion~~Basis onfor ~~the Financial Statements~~Opinion

WeThese ~~have~~financial ~~audited~~statements are the ~~accompanying~~responsibility ~~balance sheets~~ of ~~Lazuriton~~the ~~Nano~~Company’s ~~Biotechnology (U~~management.~~S.A.)~~ ~~Inc.~~Our (responsibility ~~“the~~is ~~Company”)~~to asexpress ofan ~~December~~opinion ~~31,~~on ~~2018 and 2017,~~ the ~~related~~Company’s financial statements ofbased ~~operations,~~on ~~cash~~our ~~flows,~~audits. ~~and~~We ~~stockholders’~~are ~~deficit~~a ~~for~~public ~~the~~accounting ~~years~~firm ~~then~~registered ~~ended,~~with ~~and~~ the ~~related~~Public ~~notes~~Company ~~(collectively~~Accounting ~~referred~~Oversight toBoard as(United ~~the~~States) ~~"financial statements"~~(“PCAOB”). Inand ~~our~~are ~~opinion,~~required ~~the~~to ~~financial~~be ~~statements~~independent ~~present~~with ~~fairly,~~respect into ~~all material respects,~~ the ~~financial~~Company ~~position~~in ofaccordance with the ~~Company~~U.S. atfederal ~~December~~securities ~~31,~~laws ~~2018~~ and ~~2017, and~~ the ~~results~~applicable ofrules ~~its operations~~ and ~~its~~regulations ~~cash~~of ~~flows for~~ the ~~years~~Securities ~~ended~~and ~~December~~Exchange ~~31,~~Commission ~~2018~~ and ~~2017, in conformity with~~ the UPCAOB.~~S. generally accepted accounting principles.~~

~~Basis~~We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for ~~Opinion~~the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

~~These~~Our ~~financial~~audits ~~statements~~included ~~are~~performing procedures to assess the ~~responsibility~~risks of ~~the~~material ~~Company's~~misstatement ~~management.~~of ~~Our~~the ~~responsibility~~financial isstatements, towhether ~~express~~due anto ~~opinion~~error onor ~~the~~fraud, ~~Company’s~~and ~~financial~~performing ~~statements~~procedures ~~based~~that onrespond ~~our~~to ~~audits~~those risks. WeSuch ~~are~~procedures aincluded ~~public~~examining, ~~accounting~~on ~~firm~~a ~~registered~~test ~~with~~basis, evidence regarding the ~~Public~~amounts ~~Company~~and ~~Accounting~~disclosures ~~Oversight~~in ~~Board~~the ~~(United~~financial ~~States)~~statements. ~~("PCAOB")~~Our ~~and~~audits ~~are~~also ~~required~~included toevaluating bethe ~~independent~~accounting ~~with~~principles ~~respect~~used toand ~~the~~significant ~~Company~~estimates inmade ~~accordance~~by ~~with~~management, ~~the~~as ~~U.S.~~well ~~federal~~as ~~securities~~evaluating ~~laws~~the ~~and~~overall presentation of the ~~applicable~~financial ~~rules~~statements. ~~and~~We ~~regulations~~believe ofthat ~~the~~our ~~Securities~~audits ~~and~~provide ~~Exchange~~a ~~Commission~~reasonable ~~and~~basis ~~the~~for ~~PCAOB~~our opinion.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’/s/ ~~internal~~KCCW ~~control~~Accountancy ~~over financial reporting~~Corp. ~~Accordingly, we express no such opinion.~~

~~Our~~We ~~audits~~have ~~included~~served performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as ~~well as evaluating~~ the ~~overall~~Company’s ~~presentation~~auditor ofsince ~~the financial statements~~2016. ~~We believe that our audits provide a reasonable basis for our opinion.~~

~~The~~Diamond ~~accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 2 to the financial statements~~Bar, the Company has incurred losses from operations, has a working capital deficit, and is in need of additional capital to grow its operations so that it can become profitable. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans with regard to these matters are described in Note 2. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.California

~~/s/~~July ~~KCCW~~13, ~~Accountancy Corp.~~2021

WeF-2 ~~have~~Table ~~served~~of ~~as the Company’s auditor since 2016.~~Contents

~~Diamond~~LAZURITON ~~Bar,~~NANO ~~California~~BIOTECHNOLOGY (U.S.A.) INC

~~April~~BALANCE ~~9, 2019~~SHEETS

F-2 Table of Contents

	December 31, 2019			December 31, 2018

Assets
Current assets
Cash and cash equivalents	$	1,347		$	1,197
Prepaid expenses		-			922
Total current assets		1,347			2,119

Total Assets	$	1,347		$	2,119

Liabilities and Stockholders’ Deficit

Current liabilities
Accrued expenses	$	36,595		$	15,086
Due to related parties		233,288			183,794
Total current liabilities		269,883			198,880

Total Liabilities		269,883			198,880

Stockholders' deficit
Common stock, $0.0001 par value; 750,000,000 shares authorized, 100,000,000 shares issued and outstanding		10,000			10,000
Additional paid-in capital		250,000			250,000
Accumulated deficit		(528,536	)		(456,761	)
Total stockholders' deficit		(268,536	)		(196,761	)

Total Liabilities and Stockholders' Deficit	$	1,347		$	2,119

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC
BALANCE SHEETS
	December 31, 2018			December 31, 2017
Assets
Current Assets
Cash and cash equivalents	$	1,197		$	1,193
Prepaid expenses		922			-
Total current assets		2,119			1,193
Total Assets	$	2,119		$	1,193
Liabilities and Stockholders’ Deficit
Current Liabilities
Accrued expenses	$	15,086		$	11,231
Due to related parties		183,794			94,201
Total current liabilities		198,880			105,432
Total liabilities		198,880			105,432
Stockholders' Deficit
Common stock, $0.0001 par value; 750,000,000 shares authorized, 100,000,000 shares issued and outstanding		10,000			10,000
Additional paid-in capital		250,000			250,000
Accumulated deficits		(456,761	)		(364,239	)
Total stockholders' deficit		(196,761	)		(104,239	)
Total Liabilities and Stockholders' Deficit	$	2,119		$	1,193

The accompanying notes to financial statements are an integral part of these statements.

~~The~~F-3 ~~accompanying~~Table ~~notes to financial statements are an integral part~~ of ~~these statements.~~Contents

~~F-3~~LAZURITON ~~Table~~NANO ofBIOTECHNOLOGY ~~Contents~~(U.S.A.) INC.

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.
STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017
	2018			2017
Net revenue	$	-		$	-
General and administrative expenses		92,526			175,864
Loss from operations		(92,526	)		(175,864	)
Other income
Interest income		4			8
Total other income		4			8
Loss before income taxes		(92,522	)		(175,856	)
Provision for income taxes		-			-
Net loss	$	(92,522	)	$	(175,856	)
Net loss per share
Basic and diluted	$	(0.00	)	$	(0.00	)
Weighted Average Shares Outstanding:
Basic and diluted		100,000,000			93,534,247

STATEMENTS OF OPERATIONS

~~The~~FOR ~~accompanying~~THE ~~notes~~YEAR toENDED ~~financial~~DECEMBER ~~statements~~31, ~~are~~2019 anAND ~~integral part of these statements.~~2018

F-4 Table of Contents

	2019			2018
Net revenue	$	-		$	-

General and administrative expenses		71,775			92,526

Loss from operations		(71,775	)		(92,526	)

Other income
Interest income		-			4
Total other income		-			4

Loss before income taxes		(71,775	)		(92,522	)

Provision for income taxes		-			-
Net loss	$	(71,775	)	$	(92,522	)

Net loss per share
Basic and diluted	$	(0.00	)	$	(0.00	)

Weighted Average Shares Outstanding:
Basic and diluted		100,000,000			100,000,000

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017
	2018			2017
Cash Flows from Operating Activities
Net loss	$	(92,522	)	$	(175,856	)
Changes in assets and liabilities:
Increase in prepaid expenses		(922	)		-
Increase in accrued expenses		3,855			5,551
Increase (decrease) in due to related parties		89,593			(129,430	)
Net cash provided by (used in) operating activities		4			(299,735	)
Cash Flows from Financing Activities
Issuance of common stock		-			200,000
Net cash provided by financing activities		-			200,000
Net increase (decrease) in cash and cash equivalents		4			(99,735	)
Cash and Cash Equivalents
Beginning		1,193			100,928
Ending	$	1,197		$	1,193
Supplemental Disclosure of Cash Flows
Cash paid during the year for:
Interest expenses	$	-		$	-
Income taxes	$	-		$	-

The accompanying notes to financial statements are an integral part of these statements.

~~The~~F-4 ~~accompanying~~Table ~~notes to financial statements are an integral part~~ of ~~these statements.~~Contents

~~F-5~~LAZURITON ~~Table~~NANO ofBIOTECHNOLOGY ~~Contents~~(U.S.A.) INC.

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.
STATEMENTS OF SHAREHOLDERS' DEFICIT
FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017
					Additional
	Common Stock				Paid-in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance at December 31, 2016		60,000,000	$	6,000	$	54,000	$	(188,383	)	$	(128,383	)
Common stock issued for cash on March 1, 2017		40,000,000		4,000		196,000		-		$	200,000
Net loss for the year ended December 31, 2017		-		-		-		(175,856	)		(175,856	)
Balance at December 31, 2017		100,000,000	$	10,000	$	250,000	$	(364,239	)	$	(104,239	)
Net loss for the year ended December 31, 2018		-		-		-		(92,522	)		(92,522	)
Balance at December 31, 2018		100,000,000	$	10,000	$	250,000	$	(456,761	)	$	(196,761	)

STATEMENTS OF CASH FLOWS

~~The~~FOR ~~accompanying~~THE ~~notes~~YEAR toENDED ~~financial~~DECEMBER ~~statements~~31, ~~are~~2019 anAND ~~integral part of these statements.~~ 2018

F-6 Table of Contents

	2019			2018
Cash Flows from Operating Activities
Net loss	$	(71,775	)	$	(92,522	)
Changes in assets and liabilities:
Decrease (increase) in prepaid expenses		922			(922	)
Increase in accrued expenses		21,509			3,855
Increase in due to related parties		49,494			89,593
Net cash provided by operating activities		150			4

Net increase in cash and cash equivalents		150			4

Cash and Cash Equivalents
Beginning		1,197			1,193
Ending	$	1,347		$	1,197

Supplemental Disclosure of Cash Flows
Cash paid during the year for:
Interest expenses	$	-		$	-
Income taxes	$	-		$	-

~~LAZURITON~~The ~~NANO~~accompanying ~~BIOTECHNOLOGY~~notes ~~(U.S.A.)~~to ~~INC~~financial statements are an integral part of these statements.

~~NOTES~~F-5 TOTable ~~FINANCIAL~~of ~~STATEMENTS~~Contents

~~DECEMBER~~LAZURITON ~~31,~~NANO ~~2018~~BIOTECHNOLOGY (U.S.A.) INC.

~~NOTE~~STATEMENTS 1.OF ~~ORGANIZATION~~CHANGES ~~AND~~IN ~~BUSINESS~~STOCKHOLDERS' DEFICIT

~~Lazuriton~~FOR ~~Nano~~THE ~~Biotechnology~~YEAR ~~(U.S.A.)~~ENDED ~~Inc.,~~DECEMBER ~~(the “Company”)~~31, ~~was~~2019 ~~incorporated~~AND on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company’s business plan is to market and distribute Nano fertilizers products.2018

The Company’s year-end is December 31.

					Additional
	Common Stock				Paid-in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance at December 31, 2017		100,000,000	$	10,000	$	250,000	$	(364,239	)	$	(104,239	)
Net loss		-		-		-		(92,522	)		(92,522	)
Balance at December 31, 2018		100,000,000		10,000		250,000		(456,761	)		(196,761	)
Net loss		-		-		-		(71,775	)		(71,775	)
Balance at December 31, 2019		100,000,000	$	10,000	$	250,000	$	(528,536	)	$	(268,536	)

~~NOTE~~The 2.accompanying ~~GOING~~notes ~~CONCERN~~to financial statements are an integral part of these statements.

~~These~~F-6 ~~financial~~Table ~~statements were prepared on the basis~~ of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $92,522 and $175,856 for the years ended December 31, 2018 and 2017, respectively, and had accumulated deficit of $456,761 and $364,239 as of December 31, 2018 and 2017, respectively, and it had no revenue from operations.Contents

~~The~~LAZURITON ~~Company~~NANO ~~faces~~BIOTECHNOLOGY all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth(U. ~~The Company's losses raise substantial doubt about its ability to continue as a going concern~~S.A.) ~~The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty~~INC.

~~The~~NOTES ~~Company~~TO isFINANCIAL currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, its president and a member of our board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time. These financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying financial statements.STATEMENTS

NOTE 31. ~~SUMMARY~~ORGANIZATION OFAND ~~SIGNIFICANT ACCOUNTING POLICIES~~BUSINESS

~~Basis~~Lazuriton Nano Biotechnology (U.S.A.) Inc. (the “Company”), a company in the developmental stage, was incorporated on June 2, 2015 in the State of ~~Presentation~~Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company’s business plan is to market and distribute Nano fertilizers products.

The ~~accompanying~~Company’s ~~financial~~year-end ~~statements~~is ~~and~~December ~~related notes have been prepared in conformity with accounting principles generally accepted in the United States of America~~31.

~~Use~~NOTE of2. ~~Estimates~~GOING CONCERN

~~The~~These ~~preparation of the~~ financial statements inwere ~~conformity~~prepared ~~with~~on ~~accounting principles generally accepted in~~ the ~~United~~basis ~~States~~ of ~~America~~accounting ~~requires~~principles ~~management~~applicable to ~~make~~going ~~estimates~~concern, ~~and~~which ~~assumptions~~assumes ~~that affect~~ the ~~reported~~realization ~~amounts~~ of assets and ~~liabilities~~discharge ~~and~~of ~~disclosure~~liabilities ofin ~~contingent~~the ~~assets~~normal ~~and~~course ~~liabilities~~of atbusiness. ~~the~~As ~~date~~shown ofin the accompanying financial statements, ~~and~~ the ~~amount~~Company has incurred net loss of ~~revenues~~$71,775 and ~~expenses~~$92,522 ~~during~~for the ~~reporting~~years ~~periods.~~ended ~~Management~~December ~~makes~~31, ~~these~~2019 ~~estimates~~and ~~using~~2018, ~~the~~respectively, ~~best~~and ~~information~~had ~~available~~accumulated atdeficit ~~the~~of ~~time~~$528,536 ~~the~~and ~~estimates~~$456,761 ~~are~~as ~~made.~~of ~~However~~December 31, ~~actual~~2019 ~~results~~and ~~could~~2018, ~~differ~~respectively, ~~materially~~and ~~from~~it ~~those~~had ~~results~~no revenue from operations.

~~F-7~~The ~~Table~~Company faces all the risks common to companies at development stage, including capitalization and uncertainty of ~~Contents~~funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

~~Classification~~The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, the President and a member of the board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time, however. If the Company is unable to obtain additional financing, the Company may be required to reduce the scope of its business development activities, which could harm its business plans, financial condition and operating results. Additional funding may not be available on favorable terms, if at all. These financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying financial statements.

~~Certain~~NOTE ~~classifications have been made to the prior year financial statements to conform to the current year presentation~~3. ~~The~~SUMMARY ~~reclassification~~OF ~~had~~SIGNIFICANT noACCOUNTING ~~impact on previously reported net loss or accumulated deficit.~~POLICIES

~~Cash~~Basis ~~and~~of ~~Cash Equivalents~~Presentation

~~Cash~~The ~~and~~accompanying ~~cash~~financial ~~equivalents~~statements ~~include~~and ~~cash~~related ~~and~~notes ~~all~~have ~~highly~~been ~~liquid~~prepared ~~instruments~~in conformity with ~~original~~accounting ~~maturities~~principles ofgenerally ~~three~~accepted ~~months~~in orthe ~~less~~United States of America.

~~Net~~Use ~~Income~~of ~~(Loss) Per Share~~Estimates

~~Basic~~The ~~income~~preparation ~~(loss)~~of ~~per~~the ~~share~~financial isstatements ~~computed~~in byconformity ~~dividing~~with ~~net~~accounting ~~income~~principles bygenerally ~~weighted~~accepted ~~average~~in ~~number~~the ofUnited ~~shares~~States of ~~common~~America ~~stock~~requires ~~outstanding~~management ~~during~~to ~~each~~make ~~period.~~estimates ~~Diluted~~and ~~income~~assumptions ~~per~~that ~~share~~affect isthe ~~computed~~reported byamounts ~~dividing~~of ~~net~~assets ~~loss~~and byliabilities ~~the~~and ~~weighted~~disclosure ~~average~~of ~~number~~contingent ofassets ~~shares~~and ofliabilities ~~common~~at ~~stock,~~the ~~common~~date ~~stock~~of ~~equivalents,~~the ~~and~~financial ~~potentially~~statements ~~dilutive~~and ~~securities~~the ~~outstanding~~amount ~~during~~of ~~each~~revenues ~~period.~~and Asexpenses ofduring ~~December~~the ~~31,~~reporting ~~2018~~periods. ~~and~~Management ~~2017,~~makes ~~the~~these ~~Company~~estimates ~~does~~using ~~not~~the ~~have~~best ~~any~~information ~~outstanding~~available ~~common~~at ~~stock~~the ~~equivalents;~~time ~~therefore,~~the aestimates ~~separate~~are ~~computation~~made. ofHowever, ~~diluted~~actual ~~loss~~results ~~per~~could ~~share~~differ ismaterially ~~not~~from ~~presented~~those results.

~~Income~~F-7 ~~Taxes~~Table of Contents

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of December 31, 2018 and 2017, respectively.Classification

~~The~~Certain ~~Company~~classifications ~~accounts~~have ~~for~~been ~~income~~made ~~taxes~~to ~~in accordance with ASC 740, Income Taxes, which requires that~~ the ~~Company~~prior ~~recognize~~year ~~deferred tax liabilities and assets based on the differences between the~~ financial ~~statement~~statements ~~carrying~~to ~~amounts~~conform ~~and~~to the ~~tax~~current ~~basis~~year ~~of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse~~presentation. ~~Deferred~~The ~~income~~reclassification ~~tax~~had ~~benefit~~no ~~(expense)~~impact ~~results~~on ~~from~~previously ~~the~~reported ~~change in~~ net ~~deferred~~loss ~~tax assets~~ or ~~deferred~~accumulated ~~tax liabilities~~deficit. ~~A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.~~

~~Recent~~Cash ~~Accounting~~and ~~Pronouncements~~Cash Equivalents

InCash ~~December 2017, the Securities~~ and ~~Exchange~~cash ~~Commission~~equivalents ~~issued~~include ~~Staff~~cash Accounting Bulletin ("SAB") No. 118 (as further clarified by FASB ASU 2018-05, Income Taxes (Topic 740): "Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118") to provide guidance for companies that may not have completed their accounting for the income tax effects of the Tax Cut and ~~Jobs~~all ~~Act~~highly ~~("Tax~~liquid ~~Act")~~instruments inwith ~~the~~original ~~period~~maturities of ~~enactment,~~three ~~which~~months is the period that includes December 22, 2017. SAB No. 118 provides for a provisional one-year measurement period for entities to finalize their accounting for certain income tax effects related to the Tax Act. SAB No. 118 provides guidance where: (i) the accounting for the income tax effect of the Tax Act is complete and reported in the Tax Act's enactment period, (ii) the accounting for the income tax effect of the Tax Act is incomplete and reported as provisional amounts based on reasonable estimates (to the extent determinable) subject to adjustments during a limited measurement period until complete, and (iii) accounting for the income tax effect of the Tax Act is not reasonably estimable (no related provisional amounts are reported in the enactment period) and entities would continue to apply accounting based on tax law provisions in effect prior to the Tax Act enactment until provisional amounts are reasonably estimable. SAB No. 118 requires disclosure of the reasons for incomplete accounting additional information or ~~analysis needed, among other relevant information~~less. ~~The Company is continuing to gather additional information to determine the final impact.~~

~~F-8~~Net ~~Table~~Loss ofPer ~~Contents~~Share

InBasic ~~February~~income ~~2018, the FASB issued ASU No, 2018-02, "Income Statement - Reporting Comprehensive Income~~ (~~Topic 220~~loss): ~~Reclassification~~per ofshare ~~Certain~~is ~~Tax~~computed ~~Effects~~by ~~from~~dividing ~~Accumulated~~net ~~Other Comprehensive Income". The amendments in this Update allow a reclassification from accumulated other comprehensive~~ income toby ~~retained~~weighted ~~earnings~~average ~~for~~number ~~stranded~~of ~~tax~~shares ~~effects~~of ~~resulting~~common ~~from~~stock ~~the~~outstanding ~~Tax~~during ~~Cuts~~each ~~and Jobs Act~~period. ~~Consequently,~~Diluted ~~the~~income ~~amendments~~per ~~eliminate~~share ~~the~~is ~~stranded~~computed ~~tax~~by ~~effects~~dividing ~~resulting~~net ~~from~~loss ~~the~~by ~~Tax Cuts and Jobs Act and will improve~~ the ~~usefulness~~weighted ofaverage ~~information~~number ~~reported to financial statement users. However, because the amendments only relate to the reclassification~~ of ~~the~~shares ~~income tax effects~~ of ~~the~~common ~~Tax Cuts and Jobs Act~~stock, ~~the~~common ~~underlying~~stock ~~guidance~~equivalents ~~that~~and ~~requires~~potentially ~~that~~dilutive ~~the~~securities ~~effect~~outstanding ofduring aeach ~~change in tax laws or rates be included in income from continuing operations is not affected~~period. ~~The~~At ~~amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this Update are effective for all entities for fiscal years beginning after~~ December 1531, ~~2018,~~2019 and ~~interim~~2018, ~~periods within those fiscal years. Early adoption of~~ the ~~amendments~~Company indoes ~~this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have~~ not ~~yet been issued and (2) for all other entities for reporting periods for which financial statements~~ have ~~not~~any ~~yet~~outstanding ~~been~~common ~~made~~stock ~~available~~equivalents; ~~for~~therefore, ~~issuance.~~a ~~The~~separate ~~amendments~~computation ~~in this Update should be applied either in the period~~ of ~~adoption~~diluted orloss ~~retrospectively~~per toshare ~~each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act~~ is ~~recognized.~~not ~~The Company is currently evaluating the impact of adopting this new guidance on its financial position, results of operations, statement of comprehensive income, and cash flows~~presented.

~~NOTE~~Income ~~4. ACCRUED EXPENSES~~Taxes

~~Accrued~~Income ~~expenses~~taxes ~~consist~~are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the ~~following:~~years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of both December 31, 2019 and 2018, respectively.

	December 31,		December 31,
	2018		2017
Accrued professional fees	$	12,836	$	8,922
Accrued transfer agent fees		2,250		1,383
Accrued Edgar agent service fees		-		926
Total	$	15,086	$	11,231

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities by using enacted tax rates in effect in the years the differences. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.

~~NOTE~~Recent 5.Accounting ~~DUE TO RELATED PARTIES~~Pronouncements

~~The~~In ~~Company~~December ~~has~~2019, ~~advanced~~the ~~funds~~FASB ~~from~~issued ~~its~~ASU ~~officer~~2019-12, ~~and~~Income ~~shareholder~~Taxes (Topic 740): Simplifying the Accounting for ~~working~~Income ~~capital~~Taxes, ~~purposes.~~as Aspart of ~~December~~its ~~31,~~overall ~~2018~~simplification initiative to reduce costs and ~~2017,~~complexity ~~there~~of ~~were~~applying ~~$183,794~~accounting ~~and~~standards ~~$94,201~~while ~~advances~~maintaining ~~outstanding,~~or ~~respectively~~improving the usefulness of the information provided to users of financial statements. The ~~Company~~FASB’s ~~has~~amendments ~~agreed~~primarily ~~that~~impact ~~the~~ASC ~~outstanding~~740, ~~balances~~Income ~~bear~~Taxes, 0%and ~~interest~~may ~~rate~~impact both interim and ~~are~~annual ~~due~~reporting ~~upon~~periods. ~~demand~~ASU 2019-12 will be effective for fiscal years beginning after 30December ~~days~~15, ~~written~~2020, ~~notice~~and byinterim ~~the~~periods ~~officer~~within those fiscal years and ~~shareholder~~early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.

~~NOTE~~F-8 6.Table ~~INCOME~~of ~~TAXES~~Contents

AsNOTE ~~of December 31, 2018, the Company had net operating loss carryforwards of approximately $456,761 that may be available to reduce future years’ taxable income~~4. ~~Future~~ACCRUED ~~tax~~EXPENSES benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

~~F-9~~Accrued ~~Table~~expenses consist of ~~Contents~~the following:

On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018. The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of December 31, 2018, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at December 31, 2018 and 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 14% for the years ended December 31, 2018 and 2017. The provisional remeasurement amount is anticipated to change as data becomes available allowing more accurate scheduling of the deferred tax assets and liabilities primarily related to net operating loss carryover.

	December 31, 2019		December 31, 2018
Accrued professional fees	$	32,329	$	12,836
Accrued edgar agent service fees		3,066		-
Accrued transfer agent fees		1,200		2,250
Total	$	36,595	$	15,086

~~The~~NOTE ~~provision~~5. ~~for~~DUE ~~Federal~~TO ~~income~~RELATED ~~tax consists of the following for the years ended December 31, 2018 and 2017, respectively:~~PARTIES

	For the Years Ended
	December 31,
	2018			2017
Federal income tax benefit attributable to:
Current Operations	$	19,430		$	36,930
Less: valuation allowance		(19,430	)		(36,930	)
Net provision for Federal income taxes	$	-		$	-

The Company has received advances from its officers and shareholders for working capital purposes. As of December 31, 2019 and 2018, there were $233,288 and $183,794 advances outstanding, respectively. The Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.

~~The~~NOTE ~~tax~~6. ~~effects~~INCOME ~~of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities consist of the following as of December 31, 2018 and 2017, respectively:~~TAXES

	December 31, 2018			December 31, 2017
Deferred tax asset attributable to:
Net operating loss carryover	$	95,920		$	76,490
Less: valuation allowance		(95,920	)		(76,490	)
Net deferred tax asset	$	-		$	-

As of December 31, 2019, the Company had net operating loss carryforwards of approximately $528,536 that may be available to reduce future years’ taxable income. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

The ~~difference between the effective rate reflected in the~~ provision for federal income ~~taxes~~tax onconsists ~~loss~~of ~~before taxes and~~ the ~~amounts~~following ~~determined~~for ~~by applying~~ the ~~applicable~~years ~~statutory~~ended ~~U.S.~~December ~~tax~~31, ~~rate~~2019 ~~are~~and ~~analyzed~~2018, ~~below~~respectively:

	2018			2017
	For the Years Ended
Statutory tax benefit		(21)	%		(34)	%
	December 31, 2019			December 31, 2018
Provisional remeasurement of deferred taxes		-	%		13	%
Federal income tax benefit attributable to:
Permanent items		-	%		-	%
Current operations	$	15,073		$	19,430
Change in deferred tax asset valuation allowance		21	%		21	%
Less: valuation allowance		(15,073	)		(19,430	)
Provision for income taxes		-	%		-	%
Net provision for Federal income taxes	$	-		$	-

~~For~~F-9 ~~the~~Table ~~years~~of ended December 31, 2018 and 2017, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.Contents

~~NOTE~~The 7.tax ~~SUBSEQUENT~~effects ~~EVENTS~~of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities consist of the following as of December 31, 2019 and 2018, respectively:

Management has evaluated subsequent events through the date which the financial statements are available to be issued. All subsequent events requiring recognition as of December 31, 2018 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

	December 31, 2019			December 31, 2018
Deferred tax asset attributable to:
Net operating loss carryover	$	110,993		$	95,920
Less: valuation allowance		(110,993	)		(95,920	)
Net deferred tax asset	$	-		$	-

~~******~~The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

F-10 Table of Contents

	For the Years Ended
	December 31, 2019			December 31, 2018
Statutory federal tax benefit		(21	)%		(21	)%
Change in deferred tax asset valuation allowance		21	%		21	%
Provision for income taxes	-%			-%

~~Item~~For 9.the ~~Changes~~years inended December 31, 2019 and ~~Disagreements~~2018, ~~with~~the ~~Accountants~~Company onhad ~~Accounting~~no unrecognized tax benefits and ~~Financial~~related ~~Disclosure~~interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

~~None~~NOTE 7. SUBSEQUENT EVENT

~~Item~~On 9AMarch 12, 2020, the Company formed a wholly owned subsidiary, Lazuriton Co., ~~Controls~~Ltd., ~~and~~a ~~Procedures~~foreign corporation in Taiwan for the operations in Taiwan. In May, 2021, the subsidiary was terminated by the local government due to inactivity.

Management’s ~~Conclusions~~has ~~Regarding~~evaluated ~~Effectiveness~~subsequent events through the date which the financial statements are available to be issued. All subsequent events requiring recognition as of ~~Disclosure~~December ~~Controls~~31, 2019 have been incorporated into these financial statements and ~~Procedures~~there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

~~We conducted an evaluation of the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a~~F-~~15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of December 31, 2018, the end of the year covered by this annual report on Form~~ 10~~-K.~~ ~~The~~Table ~~Disclosure Controls evaluation was done under the supervision and with the participation~~ of management, including our chief executive officer and chief financial officer, who are the same person. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer concluded that, due to our limited internal audit function and limited staff, our disclosure controls were not effective as of December 31, 2018, such that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the chief executive officer/chief financial officer, as appropriate to allow timely decisions regarding disclosure.Contents

~~Management’s~~Item ~~Report~~9. onChanges ~~Internal~~in ~~Control~~and ~~over~~Disagreements with Accountants on Accounting and Financial ~~Reporting~~Disclosure.

~~Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act~~None. Our management is also required to assess and report on the effectiveness of our internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2018. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework. During our assessment of the effectiveness of internal control over financial reporting as of December 31, 2018, management identified material weaknesses related to (i) our internal audit functions (ii) inadequate levels of review of the financial statements, (iii) a lack of segregation of duties within accounting functions and (iv) the absence of any independent directors. Therefore, our internal controls over financial reporting were not effective as of December 31, 2018.

~~Management~~Item has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel and excessive reliance on third party consultants for accounting, financial reporting and related activities9A. ~~The~~Controls ~~lack of any separation of duties, with the same person, who is our only employee who serves as both chief executive officer~~ and chief financial officer, and who does not have an accounting background and serves on a part-time basis, makes it unlikely that we will be able to implement effective internal controls over financial reporting in the near futureProcedures.

~~Due~~Management’s toConclusions ~~our~~Regarding ~~limited~~Effectiveness ~~size, segregation~~ of ~~all~~Disclosure ~~conflicting~~Controls ~~duties is not possible. However, to the extent possible, we plan to implement procedures to assure that the initiation of transactions, the custody of assets~~ and the recording of transactions will be performed by separate individuals if and when we have sufficient income to enable us to hire such individuals, and we cannot give any assurance that we will be able to hire such personnel in the near future or at all. Our financial condition makes it difficult for us to implement a system of internal controls over financial reporting.Procedures

16We ~~Table~~conducted an evaluation of ~~Contents~~the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of December 31, 2019, the end of the year covered by this annual report on Form 10-K. The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer, who are the same person. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer concluded that, due to our limited internal audit function and limited staff, our disclosure controls were not effective as of December 31, 2019, such that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the chief executive officer/chief financial officer, as appropriate to allow timely decisions regarding disclosure.

~~Until~~Management’s weReport ~~generate~~on ~~significantly~~Internal ~~greater~~Control ~~revenues and employ accounting personnel, it is doubtful that we will be able implement any system which provides us with any degree of internal controls~~ over ~~financial~~Financial reporting. Due to the nature of this material weakness in our internal control over financial reporting, there is more than a remote likelihood that misstatements which could be material to our annual or interim financial statements could not be prevented or detected. Reporting

AOur ~~material~~management ~~weakness~~is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(~~within~~f) ~~the~~and ~~meaning~~15d-15(f) ofunder ~~PCAOB~~the ~~Auditing~~Securities ~~Standard~~Exchange NoAct. 5)Our management is aalso ~~deficiency,~~required orto aassess ~~combination~~and ofreport ~~deficiencies,~~on inthe effectiveness of our internal control over financial reporting, ~~such~~in ~~that~~accordance ~~there~~with isSection a404 ~~reasonable~~of ~~possibility~~the ~~that~~Sarbanes-Oxley aAct ~~material~~of ~~misstatement~~2002 (“Section 404”). Management assessed the effectiveness of our ~~annual~~internal orcontrol ~~interim~~over financial ~~statements~~reporting ~~will~~as ~~not~~of beDecember ~~prevented~~31, or2019. ~~detected~~In onmaking athis ~~timely~~assessment, ~~basis.~~we Aused ~~significant~~the ~~deficiency~~criteria isset aforth ~~deficiency,~~by orthe aCommittee ~~combination~~of Sponsoring Organizations of ~~deficiencies,~~the Treadway Commission (COSO) in Internal Control - Integrated Framework. During our assessment of the effectiveness of internal control over financial reporting ~~that~~as isof ~~less~~December ~~severe~~31, ~~than~~2019, amanagement identified material ~~weakness~~weaknesses related to (i) our internal audit functions (ii) inadequate levels of review of the financial statements, ~~yet~~(iii) ~~important~~a ~~enough~~lack toof ~~merit~~segregation ~~attention~~of byduties ~~those~~within ~~responsible~~accounting ~~for~~functions ~~oversight~~and (iv) the absence of any independent directors. Therefore, our internal controls over financial reporting were not effective as of December 31, 2019.

~~Because~~Management has determined that our internal controls contain material weaknesses due to the absence of ~~its~~segregation ~~inherent~~of ~~limitations~~duties, ~~internal~~as ~~control~~well ~~over~~as ~~financial~~lack ~~reporting~~of ~~may~~qualified ~~not~~accounting ~~prevent~~personnel orand ~~detect~~excessive ~~misstatements~~reliance on third party consultants for accounting, financial reporting and related activities. ~~Projections~~The lack of any ~~evaluation~~separation of ~~effectiveness~~duties, towith ~~future~~the ~~periods~~same ~~are~~person, ~~subject~~who tois ~~the~~our ~~risk~~only ~~that~~employee ~~controls~~who ~~may~~serves ~~become~~as ~~inadequate~~both ~~because~~chief ofexecutive ~~changes~~officer inand ~~conditions~~chief financial officer, orand who does not have an accounting background and serves on a part-time basis, makes it unlikely that ~~the~~we ~~degree~~will ofbe ~~compliance~~able ~~with~~to ~~the~~implement ~~policies~~effective ~~and~~internal ~~procedures~~controls ~~may~~over ~~deteriorate~~financial reporting in the near future.

~~Changes~~Due to our limited size, segregation of all conflicting duties is not possible. However, to the extent possible, we plan to implement procedures to assure that the initiation of transactions, the custody of assets and the recording of transactions will be performed by separate individuals if and when we have sufficient income to enable us to hire such individuals, and we cannot give any assurance that we will be able to hire such personnel in ~~Internal~~the ~~Control~~near ~~Over~~future ~~Financial~~or ~~Reporting~~at all. Our financial condition makes it difficult for us to implement a system of internal controls over financial reporting.

~~There~~15 ~~was~~Table noof change in our internal control over financial reporting during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.Contents

~~Item~~Until 9Bwe generate significantly greater revenues and employ accounting personnel, it is doubtful that we will be able implement any system which provides us with any degree of internal controls over financial reporting. ~~Other~~Due ~~Information~~to the nature of this material weakness in our internal control over financial reporting, there is more than a remote likelihood that misstatements which could be material to our annual or interim financial statements could not be prevented or detected.

~~None~~A material weakness (within the meaning of PCAOB Auditing Standard No. 5) is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of our financial reporting.

17Because ~~Table~~of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of ~~Contents~~any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

~~PART~~Changes ~~III~~in Internal Control Over Financial Reporting

~~Item~~There ~~10.~~was ~~Directors~~no change in our internal control over financial reporting during the most recent fiscal quarter that has materially affected, ~~Executive~~or ~~Offices~~is ~~and~~reasonably ~~Corporate~~likely ~~Governance~~to materially affect, our internal control over financial reporting.

~~Directors~~Item ~~of the Company are elected by the stockholders to serve until the next shareholder meeting or their respective successors are duly elected and qualified~~9B. ~~Officers~~Other ~~of the Company are appointed by our Board of Directors to serve until their respective successors are duly appointed and qualified, or until he or she is removed from office~~Information. ~~The Board of Directors has no nominating, auditing or compensation committees.~~

~~The names and ages of our directors and executive officers are set forth below:~~None.

Directors and Executive Officers of the Company
Name	Age	Position
Chih-Yuan Hsiao	49	President, Principal Executive Officer and a member of the Board of Directors(1)
Ching-Chia Chuang	48	Secretary, Treasurer and Principal Financial Officer
Yu-Chih Hsiao	47	a member of the Board of Directors(2)
Min-Tsung Hsiao	45	a member of the Board of Directors(3)
Siu Wan Claire Hong	49	a member of the Board of Directors(4)

Table of Contents

~~___________~~PART III

~~(1) Chih-Yuan~~Item ~~Hsiao~~10. ~~will~~Directors, ~~serve~~Executive asOffices aand ~~director~~Corporate ~~until the next annual shareholder meeting~~Governance.

~~(2) Yu-Chih~~Directors ~~Hsiao~~of ~~will~~the ~~serve~~Company asare aelected ~~director~~by the stockholders to serve until the next ~~annual~~ shareholder meeting or their respective successors are duly elected and qualified. Officers of the Company are appointed by our Board of Directors to serve until their respective successors are duly appointed and qualified, or until he or she is removed from office. The Board of Directors has no nominating, auditing or compensation committees.

~~(3) Min-Tsung~~The ~~Hsiao~~names ~~will~~and ~~serve~~ages asof aour ~~director~~directors ~~until~~and ~~the~~executive ~~next~~officers ~~annual~~are ~~shareholder~~set ~~meeting.~~forth below:

(4) Siu Wan Claire Hong will serve as a director until the next annual shareholder meeting.

Directors and Executive Officers of the Company

Name	Age	Position
Chih-Yuan Hsiao	52	President, Principal Executive Officer and a member of the Board of Directors⁽¹⁾
Ching-Chia Chuang	51	Secretary, Treasurer, Principal Financial Officer and a member of the Board of Directors⁽²⁾
Yu-Chih Hsiao	50	a member of the Board of Directors⁽³⁾
Min-Tsung Hsiao	48	a member of the Board of Directors⁽⁴⁾

~~January~~___________ 30 of each year is specified in the Company’s Bylaws for the annual meeting of the Company’s shareholders. We did not hold the shareholder meeting on January 30, 2019 and do not plan to have regular annual shareholder meetings.

~~Backgrounds~~(1) ofChih-Yuan ~~Executive~~Hsiao ~~Officers~~will ~~and~~serve ~~Directors~~as a director until the next annual shareholder meeting or his earlier resignation.

~~The~~(2) ~~following~~Ching-Chia ~~information~~Chuang ~~sets~~will ~~forth~~serve the ~~background~~Board ~~and~~until ~~business~~the ~~experience~~next ofannual ~~our~~shareholder ~~directors~~meeting ~~and~~or ~~executive~~his ~~officers~~earlier resignation.

~~Chih~~(3) Yu-~~Yuan~~Chih Hsiao, ~~President,~~will ~~Principal~~serve ~~Executive~~as ~~Officer~~a ~~and~~director auntil ~~member~~the ofnext ~~our~~annual ~~Board~~shareholder ofmeeting ~~Directors~~or his earlier resignation.

~~Chih~~(4) Min-~~Yuan~~Tsung Hsiao ~~received~~will ~~his~~serve ~~Associate~~as Bachelor Degree in International Business from Lan Yang Institute of Technology in Taiwan in 1992. From January 2004 to December 2008, Mr. Hsiao was the president of Lazuriton Art and Culture Co., Ltd., a ~~business~~director ~~engaged~~until ~~in marketing and selling artwork carving products. From January 2009 to~~ the ~~present,~~next ~~Mr.~~annual ~~Hsiao~~shareholder ~~has~~meeting ~~been the president and a member of the board of directors of Lazuriton Nano Biotechnology Co., Ltd., a Taiwanese corporation,~~ or ~~the~~his ~~“Manufacturer”,~~earlier ~~which~~resignation ~~manufactures Nano fertilizer products that we will market and distribute~~. ~~As the president, Mr. Hsiao manages all operational activities of the Company, including the purchases and sales of the Nano Fertilizer Products.~~

~~Mr.~~January ~~Hsiao~~30 ~~became~~of ~~the~~each ~~President,~~year ~~Principal~~is ~~Executive~~specified ~~Officer~~in ~~and~~the aCompany’s ~~member~~Bylaws offor ~~our~~the ~~Board~~annual ofmeeting ~~Directors~~ of the Company’s ~~in June 2015~~shareholders. ~~Due~~We todid ~~Mr.~~not ~~Hsiao’s~~hold ~~extensive~~the ~~experience~~shareholder inmeeting ~~business~~on ~~development,~~January ~~operations management~~30, 2020 and ~~executive~~do ~~leadership,~~not ~~the~~plan ~~Company~~to ~~believes~~have heregular ~~complements~~annual ~~its~~shareholder ~~management~~meetings.

~~Ching-Chia~~Backgrounds ~~Chuang,~~of ~~Principal~~Executive ~~Financial~~Officers ~~Officer, Secretary~~ and ~~Treasurer~~Directors

~~Ching-Chia~~The ~~Chuang~~following ~~obtained~~information asets ~~Bachelor~~forth ~~of Arts degree in engineering and management from Yuan Ze University in 1993. From November 2011 to~~ the ~~present,~~background ~~Mr. Chuang has served as a consultant for the Manufacturer. There is a conflict of interest regarding Mr. Chuang’s role as consultant over the affairs of the Manufacturer~~ and ~~his~~business ~~position~~experience ~~as Principal Financial Officer, Secretary and Treasurer for the Company. In his role as consultant to the Company, Mr. Chuang assists in the cultivation~~ of ~~business~~our ~~relationships~~directors ~~in Asia. Additionally, Mr. Chuang assists in providing management~~ and ~~operation~~executive ~~recommendations to the Company~~officers.

18Chih-Yuan ~~Table~~Hsiao, President, Principal Executive Officer and a member of ~~Contents~~our Board of Directors

Chih-Yuan Hsiao received his Associate Bachelor Degree in International Business from Lan Yang Institute of Technology in Taiwan in 1992. From January 2004 to December 2008, Mr. ~~Chuang~~Hsiao ~~became~~was the ~~Principal~~president ~~Financial~~of ~~Officer~~Lazuriton Art and Culture Co., ~~Secretary~~Ltd., a business engaged in marketing and ~~Treasurer~~selling artwork carving products. From January 2009 to the present, Mr. Hsiao has been the president and a member of the ~~Company~~board inof ~~June~~directors 2of Lazuriton Nano Biotechnology Co., ~~2017~~Ltd., ~~Because~~a Taiwanese corporation, or the “Manufacturer”, which manufactures Nano fertilizer products that we will market and distribute. There is a conflict of interest regarding Mr. ~~Chuang~~Hsiao’s ~~has~~role ~~extensive~~as ~~background~~president inand ~~business~~board ~~negotiations~~member of the Manufacturer and ~~knowledge~~his inposition ~~budget~~as ~~management~~President, Principal Executive officer and ~~played~~member anof ~~integral~~the ~~role~~Board inof Directors for the ~~growth~~Company. ~~and~~As ~~expansion~~the president of ~~enterprises~~the Company, Mr. Hsiao manages all operational activities of the Company, ~~believes~~including hethe ~~complements~~purchases ~~its~~and ~~management~~sales of the Nano Fertilizer Products.

~~Yu-Chih~~Mr. Hsiao became the President, Principal Executive Officer and a member of our Board of Directors of the Company in June 2015. Due to Mr. Hsiao’s extensive experience in business development, operations management, and executive leadership, the Company believes he complements its management.

From January 2001 to December 2008, Yu-Chih Hsiao was the owner and engineer for Shengtai Engineering Ltd., a company located in Taiwan. Shengtai Engineering Ltd. was engaged in the business of providing electrical and plumbing maintenance and repairs to households. From January 2009 to the present, Mr. Hsiao ~~has~~works ~~been~~full ~~the~~time ~~factory~~attending ~~manager~~to of the ~~Manufacturer.~~affairs ~~Mr. Hsiao’s duties as the factory manager include overseeing the operations~~ of the ~~factory, quality control of products and the calculation of lead time for inventory~~Company. ~~Mr. Yu-Chih Hsiao graduated from Bi Hua High School in New Taipei City, Taiwan.~~

~~Mr.~~Ching-Chia ~~Hsiao~~Chuang, ~~became~~Principal aFinancial ~~member~~Officer, ofSecretary, ~~our~~Treasurer ~~Board of Directors in June 2015. Due to Mr. Hsiao’s extensive experience in the fertilizer industry~~ and ~~operation management, the Company believes he complements its management.~~Director

~~Min~~Ching-~~Tsung~~Chia ~~Hsiao~~Chuang obtained a Bachelor of Arts degree in engineering and management from Yuan Ze University in 1993. From November 2011 to the present, Mr. Chuang has served as a ~~member~~consultant for the Manufacturer. There is a conflict of ~~our~~interest ~~Board~~regarding Mr. Chuang’s role as consultant over the affairs of ~~Directors~~the Manufacturer and his position as Principal Financial Officer, Secretary and Treasurer for the Company. As a consultant to the Manufacturer, Mr. Chuang assists in the cultivation of business relationships in Asia. Additionally, Mr. Chuang assists in providing management and operation recommendations to the Company. Mr. Ching-Chia Chuang was elected to the Board by the Company’s shareholders on June 24, 2019.

~~From~~17 ~~January~~Table ~~2005 to the present, Min-Tsung Hsiao has been the owner and engineer~~ of Haoyi Engineering Ltd. located in Taiwan. Haoyi Engineering Ltd. is engaged in the business of providing electrical and plumbing maintenance and repairs to households. From January 2010, Mr. Hsiao was the president and director of Miaotien Biotechnology Ltd., a Taiwanese corporation, which is a distributor in Taiwan of the Nano fertilizer products of the Manufacturer. As of the date of this annual report, Miaotien Biotechnology Ltd. had ceased all of its operations. Contents

Mr. ~~Hsiao~~Chuang became athe ~~member~~Principal ofFinancial ~~our~~Officer, ~~Board~~Secretary and Treasurer of ~~Directors~~the Company in June ~~2015~~2, 2017. ~~Due~~Because to Mr. ~~Hsiao’s~~Chuang has extensive ~~experience~~background in ~~the~~business ~~Nano~~negotiations ~~fertilizer~~and ~~industry~~knowledge ~~and~~in ~~marketing~~budget management, and ~~selling~~played ~~such~~an ~~Nano~~integral ~~fertilizer~~role ~~products~~in the growth and expansion of enterprises, the Company believes ~~Mr.~~he ~~Hsiao~~ complements its management.

Mr. ~~Hsiao~~Chuang devotes approximately 1020 hours per ~~week~~month to the affairs of the Company.

~~Siu~~Yu-Chih ~~Wan Claire Hong~~Hsiao, a member of our Board of Directors

Siu Wan Claire Hong received a marketing, sales and public relations degree from Guangzhou University in 2001, and received a second marketing, sales and public relations degree from Guangdong Zhongshan University in 2004. From January ~~2004~~2001 to December ~~2005~~2008, ~~Ms.~~Yu-Chih ~~Hong~~Hsiao was athe ~~general~~owner ~~manager~~and engineer for ~~Cape~~Shengtai ~~Western~~Engineering ~~North~~Ltd., ina ~~North~~company ~~Sea~~located ~~City~~ in ~~Guangxi~~Taiwan. ~~Province,~~Shengtai inEngineering ~~China~~Ltd. ~~Cape Western North~~ was engaged in the business of ~~real~~providing ~~estate~~electrical ~~development.~~and ~~Ms.~~plumbing ~~Hong’s~~maintenance ~~duties at Cape Western North included overseeing the general affairs of the Company, developing new clients~~ and ~~maintaining~~repairs ~~client~~to ~~relationships~~households. From January ~~2010~~2009 to ~~June~~the ~~2015~~present, MsMr. ~~Hong~~Hsiao ~~was~~has been the ~~chief~~factory ~~executive~~manager ~~officer~~ of ~~Investment~~the ~~Groups~~Manufacturer. ~~Sci- Technology H~~Mr.K. inHsiao’s ~~Hong~~duties ~~Kong,~~as athe ~~company~~factory ~~engaged~~manager ininclude overseeing the ~~business~~operations of ~~investment banking. From January 2009 to~~ the ~~present~~factory, ~~Ms.~~quality ~~Hong~~control ~~has~~of ~~been~~products and the ~~chief~~calculation ~~executive~~of ~~officer~~lead oftime ~~Ican~~for ~~Capital~~inventory. ~~Inc~~Mr. inYu-Chih ~~Hong~~Hsiao ~~Kong,~~graduated ~~which~~from isBi inHua ~~the~~High ~~business~~School ofin ~~investment~~New ~~banking~~Taipei ~~and~~City, ~~financial planning~~Taiwan.

MsMr. ~~Hong~~Hsiao became a member of our Board of Directors in June 2015. Due to MsMr. ~~Hong~~Hsiao’s extensive experience in ~~business~~the ~~development~~fertilizer industry and ~~financial~~operation management, the Company believes ~~she~~he complements its management.

~~Chih-Yuan Hsiao, our president and a member of our board of directors, Yu-Chih Hsiao, a member of our board of directors and~~ Min-Tsung Hsiao, a member of our ~~board~~Board of directors are brothers. Ching-Chia Chuang is a cousin of Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao. Except disclosed above, there is no family relationship among the officers and directors of the Company. Directors

19From ~~Table~~January 2005 to the present, Min-Tsung Hsiao has been the owner and engineer of ~~Contents~~Haoyi Engineering Ltd. located in Taiwan. Haoyi Engineering Ltd. is engaged in the business of providing electrical and plumbing maintenance and repairs to households. From January 2010, Mr. Hsiao was the president and director of Miaotien Biotechnology Ltd., a Taiwanese corporation, which is a distributor in Taiwan of the Nano fertilizer products of the Manufacturer. As of the date of this annual report, Miaotien Biotechnology Ltd. had ceased all of its operations.

ToMr. Hsiao became a member of our ~~knowledge,~~Board ~~during~~of ~~the~~Directors ~~last~~in ~~ten~~June ~~years,~~2015. ~~none~~Due ofto ~~our~~Mr. ~~directors~~Hsiao’s ~~and~~extensive ~~executive~~experience ~~officers~~in ~~has~~the ~~been~~Nano ~~subject~~fertilizer toindustry ~~any~~and ofmarketing and selling such Nano fertilizer products, the ~~following:~~Company believes Mr. Hsiao complements its management.

·Chih-Yuan ~~A petition under the federal bankruptcy laws or any state insolvency law was filed by or against~~Hsiao, orour apresident ~~receiver,~~and ~~fiscal agent or similar officer was appointed by~~ a ~~court~~member ~~for~~of ~~the~~our ~~business~~board ~~or property~~ of ~~such person~~directors, orYu-Chih ~~any~~Hsiao, ~~partnership in which he was~~ a ~~general~~member ~~partner~~of atour orboard ~~within~~of ~~two~~directors ~~years~~and ~~before~~Min-Tsung ~~the time of such filing~~Hsiao, ora ~~any~~member ~~corporation or business association~~ of ~~which~~our heboard ~~was an executive officer at or within two years before the time~~ of ~~such~~directors ~~filing;~~are ·brothers. ~~Convicted~~Ching-Chia inChuang ~~a criminal proceeding or~~ is a ~~named~~cousin ~~subject~~ of aChih-Yuan ~~pending~~Hsiao, ~~criminal~~Yu-Chih ~~proceeding~~Hsiao ~~(excluding traffic violations~~ and ~~other~~Min-Tsung ~~minor~~Hsiao. ~~offenses);~~Except ·disclosed ~~The subject of any order~~above, ~~judgment,~~there oris ~~decree,~~no ~~not~~family ~~subsequently~~relationship ~~reversed,~~among ~~suspended~~the orofficers ~~vacated,~~and ofdirectors ~~any court~~ of ~~competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting,~~ the ~~following~~Company. ~~activities:~~

~~(i)~~18 ~~Acting~~Table as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; (ii) Engaging in any type of business practice; or (iii) Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or federal commodities laws;Contents

·To ~~The~~our ~~subject of any order~~knowledge, ~~judgment~~during ~~or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting for more than 60 days~~ the ~~right~~last often ~~such person to engage in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or commodity laws~~years, ornone ~~to be associated with persons engaged in any such activity; · Found by a court~~ of ~~competent~~our ~~jurisdiction~~directors ~~in a civil action or by the SEC to have violated any federal or state securities law,~~ and ~~the~~executive ~~judgment~~officers ~~in such civil action or finding by the SEC~~ has ~~not~~ been ~~subsequently~~subject ~~reversed, suspended, or vacated; · Found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission~~ to ~~have violated~~ any ~~federal~~of ~~commodities law, and~~ the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated; · The subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation offollowing:

~~(i)~~· ~~Any~~A petition under the federal bankruptcy laws or any state ~~securities~~insolvency orlaw ~~commodities~~was ~~law~~filed by or ~~regulation;~~against, or ~~(ii)~~a ~~Any~~receiver, ~~law~~fiscal agent or ~~regulation~~similar ~~respecting~~officer ~~financial~~was ~~institutions~~appointed by a court for the business or ~~insurance~~property ~~companies~~of ~~including~~such person, ~~but~~or ~~not~~any ~~limited~~partnership ~~to,~~in which he was a ~~temporary~~general partner at or ~~permanent~~within ~~injunction,~~two ~~order~~years ofbefore ~~disgorgement~~the ortime ~~restitution~~of such filing, ~~civil~~or ~~money~~any ~~penalty~~corporation or ~~temporary~~business orassociation ~~permanent~~of ~~cease-and-desist~~which ~~order,~~he orwas ~~removal~~an executive officer at or ~~prohibition~~within ~~order~~two years before the time of such filing; · Convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (~~iii~~excluding traffic violations and other minor offenses); ~~Any~~· ~~law~~The orsubject ~~regulation~~of ~~prohibiting~~any ~~mail~~order, judgment, or ~~wire~~decree, ~~fraud~~not orsubsequently ~~fraud~~reversed, insuspended ~~connection~~or ~~with~~vacated, of any ~~business~~court ~~entity;~~of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

·(i) ~~The~~Acting ~~subject~~as ofa futures commission merchant, orintroducing abroker, ~~party~~commodity totrading advisor, ~~any~~commodity ~~sanction~~pool oroperator, ~~order~~floor broker, ~~not~~leverage ~~subsequently~~transaction ~~reversed~~merchant, ~~suspended~~any orother ~~vacated~~person regulated by the Commodity Futures Trading Commission, or an associated person of any ~~self-regulatory~~of ~~organization~~the (foregoing, or as ~~defined~~an investment adviser, underwriter, broker or dealer in ~~Section~~securities, ~~3(a)(26)~~or as an affiliated person, director or employee of ~~the~~any ~~Exchange~~investment ~~Act~~company, ~~(15~~bank, ~~U.S.C.~~savings ~~78c(a)(26)))~~and loan association or insurance company, ~~any~~or ~~registered~~engaging ~~entity~~in ~~(as~~or ~~defined~~continuing any conduct or practice in ~~Section~~connection 1with such activity; (aii)~~(29)~~ ofEngaging ~~the~~in ~~Commodity~~any ~~Exchange~~type ~~Act~~of (7business ~~U.S.C.~~practice; 1or (aiii)~~(29))),~~ orEngaging in any ~~equivalent~~activity ~~exchange,~~in ~~association,~~connection ~~entity~~with orthe ~~organization~~purchase ~~that~~or ~~has~~sale ~~disciplinary~~of ~~authority~~any ~~over~~security ~~its~~or ~~members~~commodity or ~~persons~~in ~~associated~~connection with aany ~~member.~~violation of federal or state securities laws or federal commodities laws;

20· ~~Table~~The subject of ~~Contents~~any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or commodity laws, or to be associated with persons engaged in any such activity; · Found by a court of competent jurisdiction in a civil action or by the SEC to have violated any federal or state securities law, and the judgment in such civil action or finding by the SEC has not been subsequently reversed, suspended, or vacated; · Found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated; · The subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

No(i) ~~Compensation~~Any federal or state securities or commodities law or regulation; or (ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited to, ~~Directors.~~a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or (iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

No· ~~director~~The ~~has~~subject ~~received any compensation~~of, ~~in cash~~ or ofa ~~other~~party ~~kind~~to, ~~for~~any ~~serving~~sanction asor ~~a director~~order, ~~and we currently do~~ not ~~plan~~subsequently toreversed, ~~pay~~suspended ~~any cash~~ or ~~other~~vacated, ~~compensation~~of to any ~~person~~self-regulatory ~~for~~organization ~~serving~~ (as defined in Section 3(a)(26) ~~director.~~of ~~Our~~the ~~directors~~Exchange ~~are~~Act ~~entitled~~(15 toU.S.C. ~~reimbursement~~78c(a)(26))), ~~for~~any ~~reasonable~~registered ~~out-of-pocket~~entity ~~expenses~~(as ~~incurred~~defined in ~~connection~~Section ~~with~~1(a)(29) ~~our~~of ~~business.~~the ~~Our~~Commodity ~~Board~~Exchange ofAct ~~Directors~~(7 ~~may~~U.S.C. ~~award~~1(a)(29))), ~~special~~or ~~remuneration~~any toequivalent ~~any~~exchange, ~~director~~association, ~~undertaking~~entity ~~any~~or ~~special~~organization ~~services~~that onhas ~~our~~disciplinary ~~behalf,~~authority ~~other~~over ~~than~~its ~~services~~members ~~ordinarily~~or ~~required~~persons ofassociated with a ~~director~~member.

~~Code~~19 Table of ~~Ethics; Financial Expert~~Contents

WeNo doCompensation ~~not~~to ~~have a Code of Ethics. We do not have a financial expert on our Board of~~ Directors.

~~Committees~~No director has received any compensation, in cash or of ~~the~~other kind, for serving as a director, and we currently do not plan to pay any cash or other compensation to any person for serving as a director. Our directors are entitled to reimbursement for reasonable out-of-pocket expenses incurred in connection with our business. Our Board of Directors may award special remuneration to any director undertaking any special services on our behalf, other than services ordinarily required of a director.

~~The~~Code ~~Board~~ of Directors plans to establish an audit committee and a compensation committee at such time as it has sufficient members and resources. The audit committee will review the results and scope of the audit and other services provided by the independent auditors and review and evaluate our system of internal controls. The compensation committee will manage any stock option plan we may establish and review and recommend compensation arrangements for our officers. No final determination has yet been made as to the memberships of these committees or when we will have sufficient members and resources to establish those committees.Ethics

~~Potential~~We ~~Conflicts~~have not adopted a Code of ~~Interest~~Ethics that applies to our principal financial officer, principal accounting officer or controller, or persons performing similar functions as of the date of this report due to the Company’s size and lack of employees. We intend to adopt a Code of Ethics in the future. When we do so, we will disclose it in a current report on Form 8-K.

AsCommittees ~~we do not have an audit committee or compensation committee comprised~~ of ~~independent directors,~~ the ~~functions~~Board ~~that would have been performed by such committees are performed by our directors. Thus, there is a potential conflict~~ of interest, in that our directors and officers have the authority and discretion to determine issues concerning management compensation and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executive officers or directors as of the date of this annual report.Directors

WeThe ~~plan~~Board of Directors plans to ~~adopt~~establish an audit committee and a ~~code~~compensation ofcommittee ~~ethics~~at ~~that~~such ~~obligates~~time ~~our~~as ~~directors,~~it ~~officers~~has sufficient members and ~~employees~~resources. toThe ~~disclose~~audit ~~potential~~committee ~~conflicts~~will review the results and scope of ~~interest~~the audit and ~~prohibits~~other ~~those~~services ~~persons~~provided ~~from~~by ~~engaging~~the inindependent ~~such~~auditors ~~transactions~~and ~~without~~review and evaluate our ~~consent~~system of internal controls. The compensation committee will manage any stock option plan we may establish and review and recommend compensation arrangements for our officers. No final determination has yet been made as to the memberships of these committees or when we will have sufficient members and resources to establish those committees.

~~Chih-Yuan~~Potential ~~Hsiao,~~Conflicts ~~our president and a member~~ of our board of directors, Yu-Chih Hsiao, a member of our board of directors and Min-Tsung Hsiao, a member of our board of directors are brothers. Ching-Chia Chuang is a cousin of Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao. Except disclosed above, there is no family relationship among the officers and directors of the Company.Interest

~~Directors~~As ~~Independence~~we do not have an audit committee or compensation committee comprised of independent directors, the functions that would have been performed by such committees are performed by our directors. Thus, there is a potential conflict of interest, in that our directors and officers have the authority and discretion to determine issues concerning management compensation and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executive officers or directors as of the date of this annual report.

~~Our~~We ~~Board~~plan ofto ~~Directors~~adopt ~~is,~~a ~~currently,~~code ~~comprised~~ of ~~four~~ethics ~~members,~~that ~~three~~obligates ofour ~~whom~~directors, doofficers ~~not qualify as~~ and ~~one~~employees ofto ~~whom~~disclose ~~does~~potential asconflicts ~~independent~~of ~~directors~~interest inand ~~accordance~~prohibits ~~with~~those ~~the~~persons ~~requirements~~from ofengaging ~~the~~in ~~OTC~~such ~~Markets~~transactions ~~Group,~~without ~~Inc~~our consent.

21Chih-Yuan ~~Table~~Hsiao, our president and a member of ~~Contents~~our board of directors, Yu-Chih Hsiao, a member of our board of directors and Min-Tsung Hsiao, a member of our board of directors are brothers. Ching-Chia Chuang is a cousin of Chih-Yuan Hsiao, Yu-Chih Hsiao and Min-Tsung Hsiao. Except disclosed above, there is no any other family relationship among the officers and directors of the Company.

~~Term~~There is a potential conflict of ~~Office~~interest regarding Mr. Chih-Yuan Hsiao regarding his role as president and member of our board of directors of the Manufacturer and his position as President, Principal Executive Officer and member of the Board of Directors for the Company. In addition, there is a potential conflict of interest regarding Mr. Ching-Chia Chuang’s role as consultant over the affairs of the Manufacturer and his position as Principal Financial Officer, Secretary and Treasurer for the Company.

Each of our directors is appointed to hold office until the next annual meeting of our stockholders or until his or her respective successor is elected and qualified, or until he or she resigns or is removed from the office in accordance with the applicable provisions of Nevada law. Our officers are appointed by our Board of Directors ~~and hold office until removed by our Board of Directors or until their resignation.~~Independence

~~Beneficial~~Our ~~Ownership~~Board ~~Reporting~~of ~~Compliance~~Directors is, currently, comprised of four members, none of whom qualifies as an independent director as defined by the OTC Markets Group for the OTCQB and OTCQX.

We20 ~~are~~Table ~~not subject to Section 16(a)~~ of ~~the Securities Exchange Act of 1934, as amended.~~ Contents

~~Audit~~Term ~~Committee~~of ~~Financial Expert~~Office

~~Our~~Each ~~current~~of ~~Board~~our ~~performs~~directors ~~the~~is ~~functions~~appointed asto ~~our~~hold ~~audit~~office ~~committee.~~until ~~The~~the ~~majority~~next annual meeting of our ~~current~~stockholders ~~directors~~or ~~are~~until ~~not~~his ~~independent.~~or Anher ~~informal~~respective ~~search~~successor is ~~under~~elected ~~way~~and toqualified, ~~identify~~or auntil ~~suitable~~he ~~candidate~~or ~~for~~she ~~service~~resigns onor is removed from the office in accordance with the applicable provisions of Nevada law. Our officers are appointed by our Board of Directors asand anhold ~~independent~~office ~~director~~until ~~who~~removed ~~would~~by beour ~~qualified~~Board asof anDirectors ~~audit~~or ~~committee~~until ~~financial~~their ~~expert~~resignation.

~~Audit~~Beneficial ~~Committee~~Ownership Reporting Compliance

We ~~have~~are not ~~yet~~subject ~~appointed~~to anSection ~~audit~~16(a) ~~committee. At the present time, we believe that our Board is capable~~ of ~~analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The Company, however, recognizes~~ the ~~importance~~Securities ofExchange ~~good~~Act ~~corporate governance and intends to add additional directors to the Board and appoint an audit committee comprised entirely~~ of ~~independent directors~~1934, ~~including~~as ~~at least one financial expert~~amended.

~~Limitation~~Audit onCommittee ~~Liability~~Financial ~~and Indemnification of Directors and Officers~~Expert

~~Our~~We ~~articles~~do ofnot ~~incorporation~~have ~~provide~~an ~~that~~Audit noCommittee ~~director~~Financial orExpert ~~officer~~due ~~shall~~to ~~have~~our ~~any~~size, ~~liability~~limited torevenues and the ~~Company~~fact if that ~~person~~none ~~acted~~of inour ~~good~~securities ~~faith~~currently ~~and~~trade ~~with~~on ~~the~~any ~~same~~exchange ~~degree~~or other trading medium. The majority of ~~care~~our ~~and~~current ~~skill~~directors asare not independent. An informal search is under way to identify a ~~prudent~~suitable ~~person~~candidate infor ~~similar~~service ~~circumstances~~on the Board of Directors as an independent director who would be qualified as an audit committee financial expert.

~~Our~~Audit articles of incorporation and bylaws provide that we will indemnify our directors and officers and may indemnify our employees or agents to the fullest extent permitted by law against liabilities and expenses incurred in connection with litigation in which they may be involved because of their offices or positions with us. However, nothing in our articles of incorporation or bylaws protects or indemnifies a director, officer, employee or agent against any liability to which that person would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of that person’s office or position. To the extent that a director has been successful in defense of any proceeding, the Nevada Revised Statutes provide that the director shall be indemnified against reasonable expenses incurred in connection with the proceeding.Committee

~~Item~~We 11have not yet appointed an audit committee. ~~Executive~~Our ~~Compensation~~current Board performs the function of our Audit Committee. At the present time, we believe that our Board is capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The Company, however, recognizes the importance of good corporate governance and intends to add additional directors to the Board and appoint an audit committee comprised entirely of independent directors, including at least one financial expert.

~~SUMMARY~~Limitation ~~COMPENSATION~~on ~~TABLE~~Liability and Indemnification of Directors and Officers

~~Currently,~~Our ~~our~~articles ~~officers~~of ~~and~~incorporation ~~directors~~provide ~~receive~~that no ~~compensation~~director ~~for~~or ~~their~~officer ~~services.~~shall ~~They~~have ~~are reimbursed for~~ any ~~out-of-pocket~~liability ~~expenses~~to ~~that they incur on our behalf. In~~ the ~~future,~~Company weif ~~may~~that ~~approve~~person ~~payments~~acted ofin ~~salaries~~good tofaith ~~officers~~ and ~~directors,~~with ~~but~~the ~~currently,~~same nodegree ~~such compensation has been approved. As~~ of ~~December~~care ~~31,~~and ~~2018,~~skill ~~we did not have any benefits, such~~ as ~~health~~a orprudent ~~life~~person ~~insurance,~~in ~~available~~similar ~~to our officers and directors~~circumstances.

22Our ~~Table~~articles of ~~Contents~~incorporation and bylaws provide that we will indemnify our directors and officers and may indemnify our employees or agents to the fullest extent permitted by law against liabilities and expenses incurred in connection with litigation in which they may be involved because of their offices or positions with us. However, nothing in our articles of incorporation or bylaws protects or indemnifies a director, officer, employee or agent against any liability to which that person would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of that person’s office or position. To the extent that a director has been successful in defense of any proceeding, the Nevada Revised Statutes provide that the director shall be indemnified against reasonable expenses incurred in connection with the proceeding.

~~Summary~~Item 11. Executive Compensation.

Name and Principal Position	Year	SalaryFY($)		Bonus($)		Stock Awards($)		OptionAwards($)(1)		Non-EquityIncentive PlanCompensation($)		Change in Pension Value andNonqualifiedDeferredCompensationEarnings($)		AllOtherCompensation($)		Total ($)
Chih-Yuan Hsiao,	2018		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-
President, Principal Executive Officer and Director(1)	2017		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-
Ching-Chia Chuang,	2018		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-
Principal Financial Officer, Secretary and Treasurer(2)	2017		N/A		N/A		N/A		N/A		N/A		N/A		N/A		N/A
Ya-Ju Chang,	2017		N/A		N/A		N/A		N/A		N/A		N/A		N/A		N/A
Former Principal Financial Officer, Secretary and Treasurer(3)	2016		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-

SUMMARY COMPENSATION TABLE

~~___________~~ Currently, our officers and directors receive no compensation for their services. They are reimbursed for any out-of-pocket expenses that they incur on our behalf. In the future, we may approve payments of salaries to officers and directors, but currently, no such compensation has been approved. As of December 31, 2019, we did not have any benefits, such as health or life insurance, available to our officers and directors.

(1)	There is no employment contract with Chih-Yuan Hsiao at this time. Nor are there any agreements for compensation in the future. A salary and stock options and/or warrants program may be developed in the future.
(2)	There is no employment contract with Ching-Chia Chuang at this time. Nor are there any agreements for compensation in the future. A salary and stock options and/or warrants program may be developed in the future.
(3)	There was no employment contract between Ya-Ju Chang and the Company. Ya-Ju Chang resigned as principal financial officer, secretary and treasurer on June 2, 2017.

Table of Contents

~~Narrative Disclosure to~~ Summary Compensation ~~Table~~

Other than set out below, there are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

Name and Principal Position	Year	Salary FY ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)(1)		Non-Equity Incentive Plan Compensation ($)		Change in Pension Value and Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
Chih-Yuan Hsiao,	2019		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-
President, Principal Executive Officer and Director⁽¹⁾	2018		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-

Ching-Chia Chuang,	2019		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-
Principal Financial Officer, Secretary and Treasurer⁽²⁾	2018		-0-		-0-		-0-		-0-		-0-		-0-		-0-		-0-

~~Stock~~___________ ~~Option Plan~~

We did not adopt any Equity Incentive Plan as of December 31, 2018.

⁽¹⁾	There is no employment contract with Chih-Yuan Hsiao at this time. Nor are there any agreements for compensation in the future. A salary and stock options and/or warrants program may be developed in the future.
⁽²⁾	There is no employment contract with Ching-Chia Chuang at this time. Nor are there any agreements for compensation in the future. A salary and stock options and/or warrants program may be developed in the future.

~~Grants~~Narrative ofDisclosure ~~Plan-Based~~to ~~Awards~~Summary Compensation Table

~~Not~~Other ~~applicable~~than set out below, there are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

23Stock ~~Table~~Option ~~of Contents~~Plan

~~Outstanding~~We did not adopt any Equity ~~Awards~~Incentive atPlan ~~Fiscal~~as ~~Year~~of ~~End~~December 31, 2019.

~~The~~Grants ~~following table summarizes outstanding unexercised options, unvested stocks and equity incentive plan awards held by each~~ of ~~our~~Plan-Based ~~named executive officers, as of December 31, 2018:~~Awards

~~OUTSTANDING~~Not ~~EQUITY AWARDS AT FISCAL YEAR-END~~applicable.

~~OPTION~~22 ~~AWARDS~~Table ~~STOCK AWARDS Name Number~~ of SecuritiesUnderlyingUnexercisedOptions (#)Exercisable Number of SecuritiesUnderlyingUnexercisedOptions (#)Unexercisable Equity Incentive Plan Awards:Number ofSecuritiesUnderlyingUnexercisedUnearnedOptions(#) Options ExercisePrices($) Option ExpirationDate Number of Shares orUnits ofStock ThatHave NotVested(#) Market Value ofShares orUnits ofStock ThatHave NotVested($) Equity Incentive PlanAwards:Number ofUnearnedShares, Unitsor OtherRights ThatHave NotBeen Issued(#) Equity Incentive Plan Awards:Market or PayoutValue of UnearnedShares, Units orOther Rights ThatHave Not BeenIssued($) - - - - - - - - - -Contents

~~Option~~Outstanding ~~Exercises~~Equity ~~and~~Awards ~~Stock~~at ~~Vested~~Fiscal Year End

NoThe following table summarizes outstanding unexercised options, ~~were~~unvested ~~awarded~~stocks and equity incentive plan awards held by ~~the~~each ~~Company~~of our named executive officers, as of December 31, ~~2018.~~2019:

~~Compensation~~OUTSTANDING ofEQUITY ~~Directors~~AWARDS AT FISCAL YEAR-END

~~Our~~OPTION ~~directors~~AWARDS ~~did~~STOCK ~~not~~AWARDS ~~receive~~Name ~~compensation~~Number ~~for~~of ~~services~~Securities asUnderlying aUnexercised ~~director~~Options ~~during~~(#)Exercisable ~~the~~Number ~~fiscal~~of ~~years~~Securities Underlying Unexercised Options (#)Unexercisable Equity Incentive Plan Awards: Number of ~~2017~~Securities ~~and~~Underlying ~~2018.~~Unexercised ~~Our~~Unearned ~~directors~~Options(#) ~~are~~Options ~~entitled~~Exercise toPrices($) ~~any~~Option ~~reimbursement~~Expiration ~~for~~Date ~~travel~~Number of Shares or ~~other~~Units ~~expenses~~of ~~incurred~~Stock inThat ~~connection~~Have ~~with~~Not ~~attending~~Vested ~~meetings~~(#) Market Value of ~~the~~Shares ~~Board.~~or Units of Stock That Have Not Vested ($) Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Been Issued (#) Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Been Issued ($) - - - - - - - - - -

24Option ~~Table~~Exercises ofand ~~Contents~~Stock Vested

~~Item~~No ~~12.~~options ~~Security~~were ~~Ownership~~awarded ofby ~~Certain~~the ~~Beneficial~~Company ~~Owners~~as ~~and~~of ~~Management~~December ~~and~~31, ~~Related Stockholder Matters~~2019.

~~SECURITY~~Compensation ~~OWNERSHIP~~of OFDirectors ~~CERTAIN BENEFICIAL OWNERS AND MANAGEMENT~~

~~The~~Our ~~following~~directors ~~table~~did ~~lists,~~not asreceive ofcompensation ~~June~~for 3,services 2019, the number of shares of common stock of the Company that are beneficially owned by (i) each person or entity known to the Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each officer and director of the Company; and (iii) all officers and directors as a ~~group.~~director ~~Information~~during ~~relating to beneficial ownership of common stock by our principal shareholders and management is based upon information furnished by each person using “beneficial ownership” concepts under~~ the ~~rules~~fiscal ofyear ~~the Securities and Exchange Commission. Under these rules, a person is deemed to be a beneficial owner~~ of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security2019. ~~The~~Our ~~person~~directors isare ~~also~~entitled ~~deemed~~ to ~~be a beneficial owner of~~ any ~~security~~reimbursement offor ~~which~~travel that person has a right to acquire beneficial ownership within 60 days of the date of the respective table. Under the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or ~~she~~other ~~may~~expenses ~~not~~incurred ~~have~~in ~~any~~connection ~~pecuniary~~with ~~beneficial~~attending ~~interest.~~meetings ~~Except as noted below, each person has sole voting and investment power. For purposes~~ of ~~computing~~ the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days of the date of the respective table is deemed to be outstanding for such person, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other personBoard. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership. Beneficial ownership percentages are calculated based on shares of common stock issued and outstanding and is based on a total of 100,000,000 shares of common stock that were issued and outstanding as of June 3, 2019.

~~Unless~~23 ~~otherwise~~Table ~~noted, the business address~~ of each beneficial owner listed is 341, Sec. 2, Wanshou Road, 10th Floor, Guishan District, Taoyuan City, 333, Taiwan (Republic of China). Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power may be shared with a spouse.Contents

Name of Beneficial Owner	Amount and Nature ofBeneficialOwnership		Percentof theCommon StockIssued andOutstanding
Chih-Yuan Hsiao, President and Director		52,348,003		52.35	%
Ching-Chia Chuang, Principal Financial Officer, Secretary and Treasurer		750,000	*
Min-Tsung Hsiao, Director		4,162,500		4.16	%
Yu-Chih Hsiao, Director		3,362,500		3.36	%
Siu Wan Claire Hong		0		-
All officers and directors as a group (Five (5) persons)		60,623,003		60.62	%
Yung-Sheng Hsiao		7,514,170		7.51	%

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

~~____________~~The following table lists, as of December 31, 2019, the number of shares of common stock of the Company that are beneficially owned by (i) each person or entity known to the Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each officer and director of the Company; and (iii) all officers and directors as a group. Information relating to beneficial ownership of common stock by our principal shareholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the Securities and Exchange Commission. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days of the date of the respective table. Under the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest. Except as noted below, each person has sole voting and investment power. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days of the date of the respective table is deemed to be outstanding for such person, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership. Beneficial ownership percentages are calculated based on shares of common stock issued and outstanding and is based on a total of 100,000,000 shares of common stock that were issued and outstanding as of December 31, 2019.

Unless otherwise noted, the business address of each beneficial owner listed is 341, Sec. 2, Wanshou Road, 10th Floor, Guishan District, Taoyuan City, 333, Taiwan (1Republic of China) ~~The~~. ~~percentages~~Except ~~are~~as ~~based~~otherwise ~~on 100~~indicated,~~000,000~~ the persons listed below have sole voting and investment power with respect to all shares of our common stock ~~issued~~owned ~~and~~by ~~outstanding~~them, asexcept ofto ~~June~~the 3,extent ~~2019~~that power may be shared with a spouse.

(2) As used in this table, “beneficial ownership” means the sole or shared power to vote, or to direct the voting of, a security, or the sole or share investment power with respect to a security (i.e., the power to dispose of, or to direct the disposition of a security).

Name of Beneficial Owner	Amount and Nature of Beneficial Ownership		Percent of the Common Stock Issued and Outstanding
Chih-Yuan Hsiao, President and Director		52,348,003		52.35	%
Ching-Chia Chuang, Principal Financial Officer, Secretary and Treasurer		750,000	*
Min-Tsung Hsiao, Director		4,162,500		4.16	%
Yu-Chih Hsiao, Director		3,362,500		3.36	%
All officers and directors as a group (Five (5) persons)		60,623,003		60.62	%
Yung-Sheng Hsiao		7,514,170		7.51	%

~~25 Table of Contents~~____________

~~Item~~(1) ~~13.~~The ~~Certain~~percentages ~~Relationships~~are ~~and~~based ~~Related~~on ~~Transactions~~100,000,000 shares of common stock issued and ~~Director~~outstanding ~~Independence~~as of December 31, 2019.

~~Certain~~(2) ~~Relationships~~As ~~and~~used ~~Related~~in ~~Transactions~~this table, “beneficial ownership” means the sole or shared power to vote, or to direct the voting of, a security, or the sole or share investment power with respect to a security (i.e., the power to dispose of, or to direct the disposition of a security).

As24 ~~set~~Table ~~forth above, on February 9, 2017, Mr. Hsiao signed a written funding commitment (the “Funding Commitment”) to lend the Company as much as $400,000 to pay the operating expenses~~ of the Company for a period of 12 months. The Funding Commitment automatically renews on each anniversary of the Funding Commitment for one additional year term unless either the Company or Mr. Hsiao elects to terminate the Funding Commitment. Any amount advanced by Mr. Hsiao pursuant to that Funding Commitment shall not accrue interest and is payable on demand. As of the date of this report, there is no particular notice required to be given by Mr. Hsiao regarding that demand. We can provide no guarantee or assurance that in the event of that demand, we can pay the amount demanded, or any other amount, on the date for which such payment is due. Because Mr. Hsiao is our president and a member of our board of directors, we believe the Funding Commitment is a related party transaction. However, our board believes that the terms of the Funding Commitment are not unreasonable. As of April 3, 2019, we owed Mr. Hsiao approximately $215,000 pursuant to that Funding Commitment. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.Contents

~~The~~Item ~~Company has received advances from its officers and shareholders, including Mr~~13. ~~Chih-Yuan~~Certain ~~Hsiao~~Relationships and ~~Mr.~~Related ~~Yu-Chih Hsiao~~Transactions, ~~for working capital purposes. As of December 31, 2018~~ and ~~2017,~~Director ~~there were $183,794 and $94,201 advances outstanding, respectively~~Independence. ~~The officer and shareholder of the Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.~~

~~Other~~Certain ~~than~~Relationships as specified above, to the best of our knowledge that there are no transactions involving any director, executive officer, or any security holder who is a beneficial owner or any member of the immediate family of the officers and ~~directors,~~Related ~~or any related persons or promoters.~~Transactions

26As ~~Table~~set forth above, on February 9, 2017, Mr. Hsiao signed a written funding commitment (the “Funding Commitment”) to lend the Company as much as $400,000 to pay the operating expenses of ~~Contents~~the Company for a period of 12 months. The Funding Commitment automatically renews on each anniversary of the Funding Commitment for one additional year term unless either the Company or Mr. Hsiao elects to terminate the Funding Commitment. Any amount advanced by Mr. Hsiao pursuant to that Funding Commitment shall not accrue interest and is payable on demand. As of the date of this report, there is no particular notice required to be given by Mr. Hsiao regarding that demand. We can provide no guarantee or assurance that in the event of that demand, we can pay the amount demanded, or any other amount, on the date for which such payment is due. Because Mr. Hsiao is our president and a member of our board of directors, we believe the Funding Commitment is a related party transaction. However, our board believes that the terms of the Funding Commitment are not unreasonable. As of December 31, 2019, we owed Mr. Hsiao approximately $233,288 pursuant to that Funding Commitment. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

~~PART~~Other IVthan as specified above, to the best of our knowledge that there are no transactions involving any director, executive officer, or any security holder who is a beneficial owner or any member of the immediate family of the officers and directors, or any related persons or promoters.

~~Item~~25 ~~14.~~Table ~~Principal~~of ~~Accounting Fees and Services.~~Contents

~~Summary~~PART ~~of Principal Accounting Fees for Professional Services Rendered~~IV

~~The~~Item ~~following~~14. ~~table~~Principal ~~presents~~Accounting ~~the~~Fees ~~aggregate fees for professional audit services~~ and ~~other services rendered by KCCW Accountancy Corp~~Services.

	Year EndedDecember 31,2018		Year EndedDecember 31,2017
Audit Fees	$	26,000	$	26,000
Audit-Related Fees		-		-
Tax Fees		1,000		1,000
All Other Fees (Bookkeeping)		-		-
Total	$	27,000	$	27,000

Summary of Principal Accounting Fees for Professional Services Rendered

~~Audit~~The ~~Fees consist~~following oftable ~~fees~~presents ~~billed for~~ the ~~annual~~aggregate ~~audit~~fees offor ~~our~~professional ~~financial~~audit ~~statements~~services and other ~~audit~~ services ~~including~~rendered ~~the~~by ~~provision~~KCCW ofAccountancy ~~consents and the review of documents filed with the SEC~~Corp.

We do not have an independent audit committee and our board of directors, therefore, serves as the audit committee for all purposes relating to communication with our auditors and responsibility for our audit. All engagements for audit services, audit- related services and tax services are approved in advance by our Board of Directors. Our Board of Directors has considered whether the provision of the services described above for the fiscal year ended December 31, 2018, is compatible with maintaining the auditor’s independence.

	Year Ended December 31, 2019		Year Ended December 31, 2018

Audit Fees	$	26,000	$	26,000
Audit-Related Fees		-		-
Tax Fees		1,000		1,000
Total	$	27,000	$	27,000

~~All~~Audit ~~audit~~Fees ~~and~~consist ~~non-audit~~of ~~services~~fees ~~that~~billed ~~may~~for ~~be provided by our principal accountant to us shall require pre-approval by~~ the ~~Board~~annual audit of ~~Directors. Further,~~ our ~~auditor shall not provide those services to us specifically prohibited by the SEC, including bookkeeping or other services related to the accounting records or~~ financial statements ~~of the audit client; financial information systems design~~ and ~~implementation;~~other ~~appraisal or valuation services, fairness opinion, or contribution-in-kind reports; actuarial services; internal~~ audit ~~outsourcing~~ services; ~~management~~including ~~functions;~~the ~~human~~provision ~~resources;~~of ~~broker-dealer,~~consents ~~investment adviser, or investment banking services; legal services~~ and ~~expert services unrelated to~~ the ~~audit;~~review ~~and~~of ~~any~~documents ~~other~~filed ~~service~~with ~~that~~ the ~~Public Company Oversight Board determines, by regulation, is impermissible~~SEC.

27We ~~Table~~do not have an independent audit committee and our board of ~~Contents~~directors, therefore, serves as the audit committee for all purposes relating to communication with our auditors and responsibility for our audit. All engagements for audit services, audit- related services and tax services are approved in advance by our Board of Directors. Our Board of Directors has considered whether the provision of the services described above for the fiscal year ended December 31, 2019, is compatible with maintaining the auditor’s independence.

~~Item~~All 15audit and non-audit services that may be provided by our principal accountant to us shall require pre-approval by the Board of Directors. ~~Exhibits~~Further, our auditor shall not provide those services to us specifically prohibited by the SEC, including bookkeeping or other services related to the accounting records or financial statements of the audit client; financial information systems design and ~~Financial~~implementation; ~~Statement~~appraisal ~~Schedules~~or valuation services, fairness opinion, or contribution-in-kind reports; actuarial services; internal audit outsourcing services; management functions; human resources; broker-dealer, investment adviser, or investment banking services; legal services and expert services unrelated to the audit; and any other service that the Public Company Oversight Board determines, by regulation, is impermissible.

ExhibitNumber		Description
3.1		Articles of Incorporation (1)
3.2		Certificate of Correction to Articles of Incorporation (2)
3.3		Bylaws (3)
10.1		Marketing and Distribution Agreement with Lazuriton Nano Biotechnology Co., Ltd. dated December 1, 2015 (4)
10.2**		Summary Translation of the Office Lease Agreement
10.3		Funding Commitment of Chih-Yuan Hsiao dated February 9, 2017 (5)
31.1**		Certification of Principal Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002
32.2**		Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002
101.LAB		XBRL Taxonomy Extension Label Linkbase***
101.PRE		XBRL Taxonomy Extension Presentation Linkbase***
101 .INS		XBRL Instance Document***
101.SCH		XBRL Taxonomy Extension Schema***
101.CAL		XBRL Taxonomy Extension Calculation Linkbase***
101.DEF		XBRL Taxonomy Extension Definition Linkbase***

Table of Contents

~~____________~~Item 15. Exhibits and Financial Statement Schedules.

(1) Incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 filed on March 11, 2016.

Exhibit Number		Description

3.1		Articles of Incorporation (1)
3.2		Certificate of Correction to Articles of Incorporation (2)
3.3		Bylaws (3)
10.1		Marketing and Distribution Agreement with Lazuriton Nano Biotechnology Co., Ltd. dated December 1, 2015 (4)
10.2		Funding Commitment of Chih-Yuan Hsiao dated February 9, 2017 (5)
31.1*		Certification of Principal Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002
32.2*		Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002
101.LAB		XBRL Taxonomy Extension Label Linkbase***
101.PRE		XBRL Taxonomy Extension Presentation Linkbase***
101 .INS		XBRL Instance Document***
101.SCH		XBRL Taxonomy Extension Schema***
101.CAL		XBRL Taxonomy Extension Calculation Linkbase***
101.DEF		XBRL Taxonomy Extension Definition Linkbase***

~~(2) Incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 filed on March 11, 2016.~~____________

(31) Incorporated by reference to Exhibit 3.41 to the Registration Statement on Form S-1 filed on March 11, 2016.

(42) Incorporated by reference to Exhibit 103.12 to the Registration Statement on Form S-1 filed on March 11, 2016.

(53) Incorporated by reference to Exhibit 103.54 to the ~~Company’s~~Registration ~~annual~~Statement ~~report~~ on Form 10S-K1 filed on ~~April~~March 311, ~~2018~~2016.

**(4) ~~Filed~~Incorporated ~~herewith~~by reference to Exhibit 10.1 to the Registration Statement on Form S-1 filed on March 11, 2016.

~~Item~~(5) 16Incorporated by reference to Exhibit 10. 5 to the Company’s annual report on Form 10-K ~~Summary~~filed on April 3, 2018.

~~None~~* Filed herewith.

28Item ~~Table~~16. ofForm ~~Contents~~10-K Summary

~~SIGNATURES~~None.

~~Pursuant~~27 toTable ~~the requirements~~ of ~~Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Contents

	Lazuriton Nano Biotechnology (U.S.A) Inc.
Dated: June 14, 2019	By:	/s/ Chih-Yuan Hsiao
		Chih-Yuan Hsiao
		Principal Executive officer and Director

SIGNATURES

	Lazuriton Nano Biotechnology (U.S.A) Inc.
Dated: June 14, 2019	By:	/s/ Ching-Chia Chuang
		Ching-Chia Chuang
		Principal Financial Officer and Director

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the registrant and in the capacities and on the dates indicated.

	Lazuriton Nano Biotechnology (U.S.A) Inc.

Dated: July 22, 2021	By:	/s/ Chih-Yuan Hsiao
		Chih-Yuan Hsiao
		Principal Executive officer and Director

Name		Date
Dated: July 22, 2021	By:	/s/ Ching-Chia Chuang
/s/ Chih-Yuan Hsiao		June 14, 2019
		Ching-Chia Chuang
Chih-Yuan Hsiao, Principal Executive Officer and Director
		Principal Financial Officer and Director
/s/ Ching-Chia Chuang		June 14, 2019
Ching-Chia Chuang, Principal Financial Officer
/s/ Yu-Chih Hsiao		June 14, 2019
Yu-Chih Hsiao, Director
/s/ Min-Tsung Hsiao		June 14, 2019
Min-Tsung Hsiao, Director
		June 14, 2019
Siu Wan Claire Hong, Director

29In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the registrant and in the capacities and on the dates indicated.

Name		Date

/s/ Chih-Yuan Hsiao		July 22, 2021
Chih-Yuan Hsiao, Principal Executive Officer and Director

/s/ Ching-Chia Chuang		July 22, 2021
Ching-Chia Chuang, Principal Financial Officer

/s/ Yu-Chih Hsiao		July 22, 2021
Yu-Chih Hsiao, Director

/s/ Min-Tsung Hsiao		July 22, 2021
Min-Tsung Hsiao, Director

Filing Compare · Lazuriton Nano Biotechnology (U.S.A.) Inc.